WO1991018887A1 - Diaminopyrimidine compounds - Google Patents

Diaminopyrimidine compounds Download PDF

Info

Publication number
WO1991018887A1
WO1991018887A1 PCT/EP1991/001007 EP9101007W WO9118887A1 WO 1991018887 A1 WO1991018887 A1 WO 1991018887A1 EP 9101007 W EP9101007 W EP 9101007W WO 9118887 A1 WO9118887 A1 WO 9118887A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
methylphenylamino
methylphenyl
methyl
pyrimidine
Prior art date
Application number
PCT/EP1991/001007
Other languages
French (fr)
Inventor
Robert John Ife
Thomas Henry Brown
Colin Andrew Leach
Original Assignee
Smithkline Beecham Intercredit B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Intercredit B.V. filed Critical Smithkline Beecham Intercredit B.V.
Publication of WO1991018887A1 publication Critical patent/WO1991018887A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • C07D239/49Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50Three nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Definitions

  • the present invention relates to substituted
  • Ar is a phenyl ring which can be optionally substituted by one to three groups selected from hydroxy, halogen, CF 3 , C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, cyano, amino, carbamoyl, carboxy or C 1-4 alkanoyl;
  • R 1 is hydrogen or C 1-4 alkyl
  • R 2 and R 3 are the same or different and are each hydrogen, C 1-4 alkyl or Ar 1 where Ar 1 is as defined for Ar; or R 2 and R 3 together with the nitrogen atom to which they are attached form a saturated or unsaturated ring optionally containing one or more further heteroatoms.
  • R 4 and R 5 is hydrogen or C 1-4 alkyl; and the other is hydrogen, C 1-4 alkyl, hydroxyC 1 -4 alkyl, C 1-4 alkoxy- C 1-4 alkyl, amino, C 1-4 alkanoyl, C 1-4 alkylthioC 1-4 alkyl, Ar 2 (CH 2 ) n OC 1-4 alkyl, in which Ar 2 is an optionally substituted phenyl ring as defined for Ar and n is 0 to 4; or -(CH 2 ) m Ar 3 , in which m is 1 to 4 and Ar 3 is an optionally substituted phenyl ring as defined for Ar; or R 4 and R 5 together with the carbon atoms to which they are attached form a 5- or 6-membered ring, optionally containing one or more heteroatoms; and pharmaceutically acceptable salts thereof.
  • Ar is an unsubstituted phenyl ring or a phenyl ring substituted by 1 to 3 substituents selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy,
  • Ar is an unsubstituted phenyl ring or one substituted by two substituents selected from hydrogen, C 1-4 alkyl,
  • Ar is an unsubstituted phenyl ring or one substituted by two substituents selected from C 1-4 alkyl and C 1-4 alkoxy. Most preferably, Ar is an unsubstituted phenyl ring or one substituted by a single substituent selected from the above-noted groups, in
  • R 1 is hydrogen or C 1-4 alkyl; preferably
  • R 2 and R 3 are the same or different and are each hydrogen, C 1-4 alkyl or a ring Ar 1 or R 2 and R 3 together with the nitrogen atom to which they are attached form a saturated or unsaturated ring optionally containing one or more further heteroatoms. More suitably one of R 2 and R 3 is hydrogen or C 1-4 alkyl and the
  • R 3 together with the nitrogen atom to which they are attached form a saturated or unsaturated ring optionally containing one or more further heteroatoms.
  • R 2 and R 3 are hydrogen or C 1-4 alkyl and the other is hydrogen, C 1-4 alkyl or any Ar 1 .
  • R 2 and R 3 is hydrogen or C 1-4 alkyl and the other is a ring Ar 1 ; more preferably one of R 2 and R 3 is hydrogen and the other is a ring Ar 1 .
  • Ar 1 is an unsubstituted phenyl ring or a phenyl ring substituted as defined for Ar.
  • Ar 1 is an unsubstituted phenyl ring or a phenyl ring substituted by 1 or 2 substituents selected from
  • one of R 4 and R 5 is hydrogen or C 1-4 alkyl, and the other is hydrogen, C 1-4 alkyl, hydroxyC 1-4 alkyl, C 1-4 alkoxyC 1-4 alkyl, amino, C 1-4 alkanoyl, C 1-4 alkylthio- C 1-4 alkyl, Ar 2 (CH 2 ) n OC 1-4 alkyl, in which Ar 2 is
  • R 4 is hydrogen or C 1-4 alkyl and R 5 is
  • R 4 and R 5 together with the carbon atoms to which they are attached form a 6-membered carbocyclic ring.
  • Ar 2 is an optionally substituted phenyl ring as described for Ar; preferably Ar 2 is an
  • n 0 to 4
  • Ar 3 is an optionally substituted phenyl ring as described for Ar; preferably Ar 3 is an
  • m is l to 4,
  • preferably m is 1.
  • Suitable rings formed by R 4 and R 5 together with the carbon atoms to which they are attached, containing one or more heteroatoms include, for example, 5- or
  • compounds of structure (I) in which one or more of R 1 to R 5 is a C 3-4 alkyl group may contain an assymetric centre due to the presence of the C 3-4 alkyl group.
  • Such compounds will exist as two (or more) optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of the two are included within the scope of the present invention. Further, all diastereomeric forms possible (pure enantiomers and mixtures thereof) are within the scope of the invention.
  • the compounds of the present invention can be
  • the present invention therefore provides in a further aspect a process for the preparation of a compound of structure (I) or a pharmaceutically acceptable salt thereof which comprises reaction of a compound of
  • R 3 to R 5 are as described for structure (I)
  • X is a group displaceable by an amine, with an amine of structure ArNR 1 H in which Ar and R 1 are as described for structure (I), and optionally thereafter, forming a pharmaceutically acceptable salt.
  • Suitable groups displaceable by an amine X will be apparent to those skilled in the art and include, for example, halogen in particular chlorine, SC 1-4 alkyl such as methylthio and phenoxy.
  • Reaction of a compound of structure (II) with an amine ArR 1 NH is suitably carried out in an inert solvent at elevated temperature.
  • the reaction is carried out in the absence of a solvent in a sealed receptacle at elevated temperature.
  • an inert solvent for example dioxan, at reflux temperature.
  • Pharmaceutically acceptable acid addition salts of the compounds of structure (I) can be prepared by standard procedures by, for example, reaction with suitable organic and inorganic acids the nature of which will be apparent to persons skilled in the art.
  • pharmaceutically acceptable salts can be formed by reaction with
  • hydrochloric, sulphuric, or phosphoric acids aliphatic, aromatic or heterocyclic sulphonic acids or carboxylic acids such as, for example, citric, maleic or fumaric acids, or methyl sulphonic acid.
  • the intermediate compounds of structure (II) can be prepared by procedures analogous to those known in the art.
  • the amines of structure ArR 1 NH are available commercially or can be prepared by standard techniques well known to those skilled in the art of organic chemistry.
  • compounds of structure (II) in which R 2 and R 3 are hydrogen can be prepared by the following
  • the starting materials (A) are known or can be any starting materials (A).
  • the present invention provides compounds of structure (I) and pharmaceutically acceptable salts thereof for use in therapy.
  • compositions inhibit exogenously and endogenously stimulated gastric acid secretion and are useful in the treatment of gastrointestinal diseases in mammals, in particular humans.
  • diseases include, for example, gastric and duodenal ulcers, and Zollinger-Ellison Syndrome.
  • the compounds of structure (I) can be used in the treatment of other disorders where an anti- secretory effect is desirable for example in patients with gastritis, NSAID induced gastritis, gastric ulcers, acute upper intestinal bleeding, in patients with a history of chronic and excessive alcohol consumption, and in patients with gastro oesophageal reflux disease (GERD).
  • GSD gastro oesophageal reflux disease
  • the compounds of the present invention are usually administered in a standard
  • compositions comprising a compound of structure (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
  • suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable
  • compositions for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically
  • parenterally acceptable oil for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
  • a typical suppository formulation comprises a
  • compound of formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
  • a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
  • composition is in unit dose form such as a tablet or capsule.
  • dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral
  • administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the pharmaceutically acceptable compounds of the invention will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, subcutaneous, or
  • intramuscular dose of between 0.1 mg and 100 mg
  • the compounds of the present invention can be co-administered with further active ingredients in particular when used to treat conditions caused or
  • Such ingredients include antacids (for example magnesium carbonate or hydroxide and aluminium hydroxide), non-steroidal anti-flammatory drugs (for example indomethacin, aspirin or naproxen), steroids, or nitrite scavengers (for example ascorbic acid or aminosulphonic acid), or other drugs used for treating gastric ulcers (for example pirenzipine, prostanoids for example 16,16 dimethyl PGE 2 , or histamine H 2 -antagonists (for example, cimetidine).
  • antacids for example magnesium carbonate or hydroxide and aluminium hydroxide
  • non-steroidal anti-flammatory drugs for example indomethacin, aspirin or naproxen
  • steroids or nitrite scavengers (for example ascorbic acid or aminosulphonic acid)
  • nitrite scavengers for example ascorbic acid or aminosulphonic acid
  • other drugs used for treating gastric ulcers for example pirenzipine, prost
  • the present invention also provides in a still further aspect, a method of treatment of gastrointestinal diseases caused or exacerbated by gastric acid in mammals, including man which comprises administering to a subject in need thereof an effective amount of a compound of structure (I) or a pharmaceutically acceptable salt thereof.
  • 2,4-Dichloro-6-methylpyrimidine (1.63 g, 0.01 m) and N-methylaniline (2.14 g, 0.02 m) were mixed at room temperature and heated with stirring in an oil-bath at ⁇ 150° for two hours .
  • the resulting pale-yellow oil was dissolved in water and the aqueous solution basified with saturated aqueous Na 2 CO 3 solution.
  • the mixture was extracted with ether and the ethereal solution washed with water and brine, dried and evaporated to dryness to give an oil.
  • Example 8(ii) gave after addition of acetone, a red solution (no solid crystallised at this stage). Diethyl ether was added to this solution and after standing overnight in the fridge a solid separated and was collected, washed with acetone/ diethyl ether and dried to give a light-grey powder
  • Example 18 (i) above 13.0 g, 0.057 m
  • phosphorous oxychloride (200 ml) were heated together at reflux temperature for two hours.
  • the POCl 3 was distilled off and ice added carefully to the residue which was then basified with sodium hydroxide.
  • the aqueous mixture was extracted with chloroform and the combined organic extracts dried and evaporated to dryness.
  • the residue was chromatographed on silica gel in chloroform and appropriate fractions combined, evaporated and the residue triturated with pentane to yield the title
  • Example 18 (ii) above (2.5 g, 0.01 m) and aniline (0.93 g, 0.01 m) were heated at reflux
  • N-methylaniline (1.07 g, 0.01 m) in dry tetrahydrofuran (30 ml) was heated at reflux temperature for six hours.
  • 6-Amino-2-(nitroamino)pyrimidin-4-one (4.28 g, 25 mmol) and o-toluidine (6.42 g, 60 mmol) were added to dry pyridine (50 ml), and the mixture heated to reflux for 48 hours. The pyridine was evaporated in vacuo, and the oily residue boiled with ethyl acetate, then allowed to cool. The resulting solid was mainly unreacted starting
  • iodomethane (7.81 g, 55 mmol). The mixture was heated under reflux for 3h, then stirred at room temp, for 16h. Excess iodomethane was evaporated off, and the solution acidified to pH 4 with glacial acetic acid. The white solid which precipitated was filtered off, washed with water and dried to give the title compound (9.88 g), m.p. 178°C.
  • 6-Methyl-2-methylthio-4-oxo-5-(2-hydroxyethyl)- pyrimidine (32.2 g, 0.186 mol) was added in portions to a stirred suspension of pet. ether-washed 60% sodium hydride (17.5 g, 0.437 mol) in dry dimethylformamide (400 ml) at a temperature of 30-40°C. The mixture was stirred for 30 min at this temperature, then a solution of benzyl bromide (32.9 g, 0.192 mol) in dimethylformamide (50 ml) was added dropwise over 10 min to the stirred mixture.
  • 6-Methyl-2-[(2-methylphenyl)amino]-4-(N- methylphenylamino)-5-(2-benzyloxyethyl)pyrimidine (2.3 g, 5.25 mmol) was mixed with 10% palladium on carbon in absolute ethanol (100 ml) and hydrogenated at 50 psi and 50°C for 12 hours.
  • the product obtained by evaporation of the filtrate was crystallized from ethanol/diethyl ether and finally purified by silica gel chromatography, eluted with CHCl 3 /MeOH (25:1). The product was obtained as a pale grey solid; yield 0.4 g (22%), m.p. 98-100°C.
  • Triethylamine (3.821 g, 0.375 mol) was then added and the mixture allowed to warm to room temperature. Water (100 ml) was added and the mixture extracted with
  • Example 47 2-[(2-Methylphenylamino-4-(N-methyl-2-methylphenylamino)- 6,6-dioxo-5,7-dihydrothieno[3,4-d]pyrimidine A solution of m-chloroperbenzoic acid (3.56 g, 0.0207 mol) in dry dichloromethane (20 ml) was added dropwise with stirring to a solution of 2-[(2-methylphenyl)amino]- 4-(N-methyl-2-methylphenyl)amino-5,7- dihydrothieno[3,4-d]pyrimidine (2.5 g, 0.0069 mol) in dry dichloromethane (50 ml) at 25-30°C.
  • the mixture was stirred at room temperature for 16 hours, ammonia gas bubbled through the solution for 10 min, and the deposited solid filtered off and discarded.
  • the filtrate was columned on silica gel, eluted with chloroform. A second column was required to obtain the product as a pale brown solid, m.p. 177-179°C.
  • Lyophilised gastric vesicles were prepared from pig fundic mucosa after the method of Keeling et. al.
  • K + -stimulated ATPase activity was determined at 37° in the presence of the following : 10 mM Pipes/Tris buffer pH 7.0, 2 mM MgSO 4 , 1 mM KCl, 2 mM Na 2 ATP and 3-6 ⁇ g protein/ml lyophilised gastric vesicles. After incubation for 30 minutes, the inorganic phosphate hydrolysed from ATP was determined by the method of Yoda and Hokin
  • the compounds of the examples had IC 50 values of less than 50 ⁇ M.
  • a tablet for oral administration is prepared by combining
  • Example B An injection for parenteral administration is prepared from the following
  • the compound of structure (I) is dissolved in the citric acid and the pH slowly adjusted to pH 3.2 with the sodium hydroxide solution. The solution was then made up to 100 ml with water, sterilised by filtration and sealed into appropriately sized ampoules and vials.

Abstract

Diaminopyrimidine compounds and their use as inhibitors of gastric acid secretion.

Description

DIAMINOPYRIMIDINE COMPOUNDS
The present invention relates to substituted
2,4-diaminopyrimidine derivatives, processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy. Accordingly the present invention provides, in a first aspect compounds of structure (I)
Figure imgf000003_0001
in which
Ar is a phenyl ring which can be optionally substituted by one to three groups selected from hydroxy, halogen, CF3, C1-4alkyl, C1-4alkoxy, C1-4alkylthio, cyano, amino, carbamoyl, carboxy or C1-4alkanoyl;
R1 is hydrogen or C1-4alkyl;
R2 and R3 are the same or different and are each hydrogen, C1-4alkyl or Ar1 where Ar1 is as defined for Ar; or R2 and R3 together with the nitrogen atom to which they are attached form a saturated or unsaturated ring optionally containing one or more further heteroatoms. one of R4 and R5 is hydrogen or C1-4alkyl; and the other is hydrogen, C1-4alkyl, hydroxyC1 -4alkyl, C1-4alkoxy- C1-4alkyl, amino, C1-4alkanoyl, C1-4alkylthioC1-4alkyl, Ar2(CH2)nOC1-4alkyl, in which Ar2 is an optionally substituted phenyl ring as defined for Ar and n is 0 to 4; or -(CH2)mAr3, in which m is 1 to 4 and Ar3 is an optionally substituted phenyl ring as defined for Ar; or R4 and R5 together with the carbon atoms to which they are attached form a 5- or 6-membered ring, optionally containing one or more heteroatoms; and pharmaceutically acceptable salts thereof.
Suitably, Ar is an unsubstituted phenyl ring or a phenyl ring substituted by 1 to 3 substituents selected from hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy,
C1-4alkanoyl or trif luoromethyl. More suitably, Ar is an unsubstituted phenyl ring or one substituted by two substituents selected from hydrogen, C1-4alkyl,
C1-4alkoxy, C1-4alkylthio, halogen, cyano, amino,
hydroxy, carbamoyl, carboxy, C1-4alkanoyl or trifluoromethyl. More preferably, Ar is an unsubstituted phenyl ring or one substituted by two substituents selected from C1-4alkyl and C1-4alkoxy. Most preferably, Ar is an unsubstituted phenyl ring or one substituted by a single substituent selected from the above-noted groups, in
particular hydroxy, halogen, C1-4alkyl or C1-4alkoxy. Suitably R1 is hydrogen or C1-4alkyl; preferably
R1 is C1-4alkyl. Most preferably R1 is methyl.
Suitably R2 and R3 are the same or different and are each hydrogen, C1-4alkyl or a ring Ar1 or R2 and R3 together with the nitrogen atom to which they are attached form a saturated or unsaturated ring optionally containing one or more further heteroatoms. More suitably one of R2 and R3 is hydrogen or C1-4alkyl and the
other is hydrogen, C1-4alkyl or a ring Ar1 or R2 and
R3 together with the nitrogen atom to which they are attached form a saturated or unsaturated ring optionally containing one or more further heteroatoms. Most
suitably, one of R2 and R3 is hydrogen or C1-4alkyl and the other is hydrogen, C1-4alkyl or any Ar1.
Preferably one of R2 and R3 is hydrogen or C1-4alkyl and the other is a ring Ar1; more preferably one of R2 and R3 is hydrogen and the other is a ring Ar1. Suitably Ar1 is an unsubstituted phenyl ring or a phenyl ring substituted as defined for Ar. Preferably Ar1 is an unsubstituted phenyl ring or a phenyl ring substituted by 1 or 2 substituents selected from
C1-4alkyl and halogen.
Suitably, one of R4 and R5 is hydrogen or C1-4alkyl, and the other is hydrogen, C1-4alkyl, hydroxyC1-4alkyl, C1-4alkoxyC1-4alkyl, amino, C1-4alkanoyl, C1-4alkylthio- C1-4alkyl, Ar2(CH2)nOC1-4alkyl, in which Ar2 is
an optionally substituted phenyl ring as described for Ar and n is 0 to 4, or -(CH2)mAr3 in which Ar3 is an
optionally substituted phenyl ring as described for Ar and m is 1 to 4; or R4 and R5 together with the carbon
atoms to which they are attached form a 5- or 6-membered ring optionally containing one or more heteroatoms.
Preferably R4 is hydrogen or C1-4alkyl and R5 is
C1-4alkyl, hydroxyC1-4alkyl or C1-4alkoxyalkyl; or
R4 and R5 together with the carbon atoms to which they are attached form a 6-membered carbocyclic ring. Suitably Ar2 is an optionally substituted phenyl ring as described for Ar; preferably Ar2 is an
unsubstituted phenyl ring. Suitably n is 0 to 4,
preferably n is 1.
Suitably Ar3 is an optionally substituted phenyl ring as described for Ar; preferably Ar3 is an
unsubstituted phenyl ring. Suitably m is l to 4,
preferably m is 1.
Suitable rings formed by R4 and R5 together with the carbon atoms to which they are attached, containing one or more heteroatoms include, for example, 5- or
6-membered rings containing a sulphur, oxygen or nitrogen atom and, in addition, 5- or 6-membered rings containing a sulphur atom in which the sulphur atom is in the form of the sulphoxide or sulphone, as hereinafter described in the examples. C1-4alkyl groups (either alone or as part of
another group) can be straight or branched.
It will be appreciated that compounds of structure (I) in which one or more of R1 to R5 is a C3-4alkyl group (either alone or as part of another group) may contain an assymetric centre due to the presence of the C3-4alkyl group. Such compounds will exist as two (or more) optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of the two are included within the scope of the present invention. Further, all diastereomeric forms possible (pure enantiomers and mixtures thereof) are within the scope of the invention. The compounds of the present invention can be
prepared by processes analogous to those known in the art. The present invention therefore provides in a further aspect a process for the preparation of a compound of structure (I) or a pharmaceutically acceptable salt thereof which comprises reaction of a compound of
structure (II)
Figure imgf000007_0001
in which R3 to R5 are as described for structure (I), and X is a group displaceable by an amine, with an amine of structure ArNR1H in which Ar and R1 are as described for structure (I), and optionally thereafter, forming a pharmaceutically acceptable salt.
Suitable groups displaceable by an amine X will be apparent to those skilled in the art and include, for example, halogen in particular chlorine, SC1-4alkyl such as methylthio and phenoxy.
Reaction of a compound of structure (II) with an amine ArR1NH is suitably carried out in an inert solvent at elevated temperature. Preferably the reaction is carried out in the absence of a solvent in a sealed receptacle at elevated temperature. Most preferably in an inert solvent for example dioxan, at reflux temperature. Pharmaceutically acceptable acid addition salts of the compounds of structure (I) can be prepared by standard procedures by, for example, reaction with suitable organic and inorganic acids the nature of which will be apparent to persons skilled in the art. For example, pharmaceutically acceptable salts can be formed by reaction with
hydrochloric, sulphuric, or phosphoric acids; aliphatic, aromatic or heterocyclic sulphonic acids or carboxylic acids such as, for example, citric, maleic or fumaric acids, or methyl sulphonic acid.
The intermediate compounds of structure (II) can be prepared by procedures analogous to those known in the art. The amines of structure ArR1NH are available commercially or can be prepared by standard techniques well known to those skilled in the art of organic chemistry.
For example, compounds of structure (II) in which R2 and R3 are hydrogen can be prepared by the following
procedure :
Figure imgf000008_0001
(i) POCl3.
The starting materials (A) are known or can be
prepared by standard procedures.
Compounds of structure (II) in which R3 is other than hydrogen can be prepared by the following procedures :
Figure imgf000009_0001
(i) CH3I;
(ii) R3NH2
(iii) POCl3 Compounds (B) are known or can be prepared by standard techniques.
The compounds of structure (I) and their
pharmaceutically acceptable salts exert an anti-secretory effect by inhibition of the gastrointestinal H+K+ATPase enzyme.
In a further aspect therefore the present invention provides compounds of structure (I) and pharmaceutically acceptable salts thereof for use in therapy.
The compounds of structure (I) and their
pharmaceutically acceptable salts inhibit exogenously and endogenously stimulated gastric acid secretion and are useful in the treatment of gastrointestinal diseases in mammals, in particular humans. Such diseases include, for example, gastric and duodenal ulcers, and Zollinger-Ellison Syndrome. Further, the compounds of structure (I) can be used in the treatment of other disorders where an anti- secretory effect is desirable for example in patients with gastritis, NSAID induced gastritis, gastric ulcers, acute upper intestinal bleeding, in patients with a history of chronic and excessive alcohol consumption, and in patients with gastro oesophageal reflux disease (GERD).
In therapeutic use, the compounds of the present invention are usually administered in a standard
pharmaceutical composition.
The present invention therefore provides in a further aspect pharmaceutical compositions comprising a compound of structure (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
The compounds of structure (I) and their
pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a
suspending agent, preservative, flavouring or colouring agent. A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
A composition in the form of a capsule can be
prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable
pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically
acceptable salt in a sterile aqueous carrier or
parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
A typical suppository formulation comprises a
compound of formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
Preferably the composition is in unit dose form such as a tablet or capsule. Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral
administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
The pharmaceutically acceptable compounds of the invention will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, subcutaneous, or
intramuscular dose of between 0.1 mg and 100 mg,
preferably between 0.1 mg and 25 mg, of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more. In addition, the compounds of the present invention can be co-administered with further active ingredients in particular when used to treat conditions caused or
exacerbated by gastric acidity. Such ingredients include antacids (for example magnesium carbonate or hydroxide and aluminium hydroxide), non-steroidal anti-flammatory drugs (for example indomethacin, aspirin or naproxen), steroids, or nitrite scavengers (for example ascorbic acid or aminosulphonic acid), or other drugs used for treating gastric ulcers (for example pirenzipine, prostanoids for example 16,16 dimethyl PGE2, or histamine H2-antagonists (for example, cimetidine).
The present invention also provides in a still further aspect, a method of treatment of gastrointestinal diseases caused or exacerbated by gastric acid in mammals, including man which comprises administering to a subject in need thereof an effective amount of a compound of structure (I) or a pharmaceutically acceptable salt thereof.
The following examples illustrate the invention. Temperatures are recorded in degrees centigrade.
Example 1
2-Amino-4-methγl-6-[(2-methylphenyl)amino]pyrimidine hydrochloride
2-Amino-4-chloro-6-methylpyrimidine (2.0 g, 0.014 m) and o-toluidine (4.0 g - excess) were mixed at room temperature and heated with stirring under nitrogen in an oil-bath. The oil-bath temperature was raised to 165°, held thus for two hours and the reactants then cooled to room temperature. Acetone was added to the resulting oil and on scratching a crystalline solid separated. After standing at ~0º overnight the solid was collected washed with acetone and dried (3.47 g, pale-pink solid). This solid was re-crystallised from absolute ethanol/diethyl ether to give the title compound as its hydrochloride salt (2.64 g), m.p. = 229-231°.
C12H14N4. HCl.
Found: C 57.7, H 6.1, N 22.3, Cl- 14.0
Requires: C 57.5, H 6.0, N 22.4, Cl- 14.1
Example 2
2-Amino-4,5-dimethyl-6-[ (2-methylphenyl)amino]pyrimidine hydrochloride
Substituting 2-amino-4-chloro-5,6-dimethyl-pyrimidine (2.1 g, 0.0133 m) for 2-amino-4-chloro-6-methylpyrimidine and using corresponding molar proportions of the other reagents in Example 1 produced a solid (3.16 g). This solid was re-crystallised from isopropanol to give the title compound (2.63 g) as its hydrochloride salt, m.p. = 305-306°
C13H16N4. HCl.
Found: C 58.8, H 6.4, N 21.1, Cl- 13.2
Requires: C 59.0, H 6.5, N 21.2, Cl- 13.4
Example 3
2-Amino-4-[(2-methylphenyl)amino]pyrimidine
2-Amino-4-chloropyrimidine (2.2 g, 0.01698 m) and o-toluidine (4.0 g, excess) were mixed at room temperature and heated with stirring (under an air condenser) in an oil-bath at 165-170° for two hours. After cooling the violet oil was taken up in a small volume of water and 2N HCl added dropwise with stirring to give a suspension at pH 4.5. This was extracted with chloroform (4 x 200 ml) to remove o-toluidine. The aqueous solution remaining was basified with NaOH (→ pH 8.5) and again extracted with chloroform (4 x 200 ml). The latter chloroform extracts were combined, dried (K2CO3) and evaporated to dryness to give a glass which crystallised on
standing. This material was re-crystallised from
ethanol/water to give the title compound (1.64 g) as a very pale-pink solid, m.p. = 118-120°.
C11H12N4
Found: C 65.8, H 6.0, N 27.9
Requires: C 66.0, H 6.0, N 28.0 Example 4
2-Amino-4-methyl-6-(N-methylphenylamino)pyrimidine
hydrochloride Substituting N-methylaniline (4.0 g - excess) for o-toluidine and using corresponding molar proportions of the other reagents in Example 1 gave a white solid (2.0 g). This was re-crystallised from ethanol/ether to give the title compound (1.21 g) as its hydrochloride salt,
m.p. = 243-245°.
C12H14N4· HCl.
Found: C 57.4, H 5.9, N 22.6
Requires: C 57.5, H 6.0, N 22.4 Example 5
2,4-Bis-[(2-methylphenyl)amino]-6-methylpyrimidine
hydrochloride 2,4-Dichloro-6-methylpyrimidine (1.63 g, 0.01 m) and o-toluidine (4.28 g, 0.04 m) were mixed at room temperature and heated with stirring in an oil-bath at ~150° for two hours. The cooled reaction mixture was treated with acetone to give a white solid in a pinky-red solution. The solid was collected, washed with acetone and dried to give the title compound (2.65 g) as its hydrochloride salt, m.p. = 216-218°.
C19H20N4. HCl.
Found: C 67.2, H 6.2, N 16.6, Cl- 10.0
Requires: C 67.0, H 6.2, N 16.4, Cl- 10.4
Example 6
2,4-Bis-(N-methylphenylamino)-6-methylpyrimidine
2,4-Dichloro-6-methylpyrimidine (1.63 g, 0.01 m) and N-methylaniline (2.14 g, 0.02 m) were mixed at room temperature and heated with stirring in an oil-bath at ~150° for two hours . The resulting pale-yellow oil was dissolved in water and the aqueous solution basified with saturated aqueous Na2CO3 solution. The mixture was extracted with ether and the ethereal solution washed with water and brine, dried and evaporated to dryness to give an oil. This oil was chromatographed on silica gel using methylene chloride as eluting solvent. Fractions were monitored by t.l.c. and appropriate fractions combined and evaporated to give a white solid which was triturated with 40-60 petroleum ether, filtered and dried to give the title compound (0.63 g), m.p. = 63-65°.
C19H20N4
Found: C 75.0, H 6.7, N 18.2
Requires: C 75.0, H 6.6, N 18.4
Example 7
2-(N-Methylphenylamino)-4-[(2-methylphenyl)amino]-6- methylpyrimidine hydrochloride
(i) 4-Chloro-6-methyl-2-(N-methylphenylamino)pyrimidine
6-Methyl-2-(N-methylphenylamino)pyrimidin-4-one
(J. Het. Chem. (1984), 21, 1161) (4.6 g, 0.0214 m) and phosphorous oxychloride (20 ml) were mixed at room
temperature and heated together at reflux temperature for two hours. The dark-brown solution was cooled and poured onto ice to produce, after decomposition of excess
reagent, a yellow acidic solution. This was basified (→ pH 8) with 6N. NaOH and the aqueous mixture extracted with ethyl acetate. The brown organic solution was washed with water, dried and evaporated to give the title compound as a brown oil, 3.06 gms (Mass spectrum M-H = 232). (ii) 2-(N-methylphenylamino)-4-[(2-methylphenylamino]-6- methylpyrimidine hydrochloride.
4-Chloro-6-methyl-2-(N-methylphenylamino) pyrimidine (3.0 g, oil, 0.0129 m) and o-toluidine (1.38 g, 0.0129 m) were mixed at room temperature and heated in an oil-bath, with stirring, to 140°. After twenty minutes at this temperature the mixture completely solidified. After cooling acetone was added and the solid collected, ground to a powder, washed with more acetone and dried (3.85 g). This solid was re-crystallised from ethanol/ether to give the title compound (2.48 g) as its hydrochloride salt, light-buff, m.p. = 238-240°.
C19H20N4. HCl.
Found: C 66.9, H 5.9, N 16.4, Cl- 10.2
Requires: C 67.0, H 6.2, N 16.4, Cl- 10.4
Example 8 2-[(2-Methylphenyl)amino]-4-(N-methylphenylamino)-6- methylpyrimidine hydrochloride
(i) 4-Chloro-6-methyl-2-[(2-methylphenyl)amino]pyrimidine Substituting 6-methyl-2-[(2-methylphenyl)amino]- pyrimidin-4-one (J.C.S. (1946), 351) (3.63 g, 0.0159 m) for 6-methyl-2-(N-methylphenylamino)pyrimidin-4-one and using corresponding molar proportions of the other reagents in Example 7(i) gave the title compound as an oil (3.94 g), which crystallised on standing under vacuum overnight.
(ii) 2-[(2-Methylphenyl)amino]-4-(N-methylphenylamino)- 6-methylpyrimidine hydrochloride. 4-Chloro-6-methyl-2-[(2-methylphenyl)amino]pyrimidine (3.9 g, 0.01674 m) and N-methylaniline (1.79 g, 0.01674 m) were mixed at room temperature and heated with stirring in an oil-bath at 140° for three hours. The red-oil produced was cooled to ~50° and acetone added to give, on
scratching a light buff solid which was collected, washed with acetone and dried (3.56 g). This solid was
re-crystallised from ethanol/ether to give the title compound (3.01 g) as light-buff needles, m.p. = 203-205° (hydrochloride salt).
C 19H20N4. HCl.
Found: C 66.9, H 6.3, N 16.5, Cl- 10.3
Requires: C 67.0, H 6.2, N 16.4, Cl- 10.4 Example 9
2-[(2-Methylphenyl)amino]-4-(phenylamino)-6-methyl- pyrimidine hydrochloride Substituting aniline (0.718 g, 0.00644 m) for
N-methylaniline and using corresponding molar proportions of the other reagents in Example 8(ii), gave a buff- coloured solid (1.33 g). This was re-crystallised from ethanol/diethyl ether to give the title compound (1.04 g) as its hydrochloride salt (pale-buff), m.p. = 212-214°.
C 18H18N4. HCl.
Found: C 65.9, H 5.9, N 17.0
Requires: C 66.2, H 5.9, N 17.1 Example 10
2-[(2-Methylphenyl)amino]-4-(N-methyl-2-methylphenylamino)- 6-methylpyrimidine hydrochloride Substituting N-methyl-o-toluidine (0.935 g, 0.00772 m) for N-methylaniline and using corresponding molar
proportions of the other reagents in Example 8(ii), gave after addition of acetone, a red solution (no solid crystallised at this stage). Diethyl ether was added to this solution and after standing overnight in the fridge a solid separated and was collected, washed with acetone/ diethyl ether and dried to give a light-grey powder
(0.7 g). This was crystallised from acetone/diethyl ether to give the title compound (0.35 g) as its hydrochloride salt, m.p. = 179-180°.
C20H22N4. HCl.
Found: C 67.3, H 6.5, N 15.2
Requires: C 67.7, H 6.5, N 15.8 Example 11
2-Amino-4-[(2-methylphenyl)amino]-6-n-propyl pyrimidine.
(i) 2-Amino-4-chloro-6-n-propylpyrimidine
2-Amino-6-n-propylpyrimidin-4-one (J.C.S.(C), (1968), 2358-67) (6.7 g, 0.0437 m) and phosphorus oxychloride (40 ml) were mixed at room temperature and heated at reflux temperature for three hours to produce an orange solution. This was cooled, poured onto ice and stirred for several hours. The aqueous medium was neutralised with 6N. NaOH and again stirred in ice. A brown solid precipitate resulted which was extracted into ethyl acetate. The organic extracts were combined, washed, dried and evaporated to give a buff solid which was immediately used in the next stage of the synthesis
(Mass spectrum→ M/e = 171). (ii) 2-Amino-4-[(2-methylphenyl)amino]-6-n-propyl
pyrimidine
2-Amino-4-chloro-6-n-propylpyrimidine (1.65,
0.00965 m) and o-toluidine (4.0 g - excess) were mixed at room temperature and heated with stirring in an oil-bath at 140° for four hours. After cooling acetone was added to give a purply-red solution. Diethylether was added to precipitate a purple oil. The solution was decanted off and the residual oil triturated several times with
diethylether. The oil was dissolved in acetone, water added and the purple solution basified with aqueous
Na2CO3 when a solid precipitated which was collected, washed with water and dried (2.25 g). This material was crystallised from acetone/water to give the title compound (1.55) as buff needles, m.p. = 151-153°.
C14H18N4
Found: C 69.4, H 7.5, N 23.3
Requires: C 69.4, H 7.5, N 23.1
Example 12
2-Amino-4-(2-methyl-4-hydrosyphenylamino)-6-n-propyl- pyrimidine
Substituting 4-amino-m-cresol (4.0 gms, XS) for o-toluidine and using corresponding molar proportions of the other reagents in Example 11(ii) gave a dark-red solution after addition of acetone to the reaction
mixture. Water was added followed by aqueous Na2CO3 to basify the solution and precipitate a black solid which was filtered off and discarded. The aqueous filtrate was extracted with ethyl acetate and the combined organic extracts back-washed with water. The ethyl acetate was dried and evaporated to yield a dark-brown glass which solidified on treatment with diethyl ether and was
collected, washed with ether and dried to a buff powder (2.72 g). This was charcoated in ethanol, concentrated and stood at 0° to give the title compound (1.14 g) as a buff-coloured crystalline solid, m.p. = 199-200°.
C14H18N4O
Found: C 64.8, H 6.9, N 21.7
Requires: C 65.1, H 7.0, N 21.7
Example 13
2-[(2-Methylphenyl)amino]-4-(N-methylphenylamino)-6-n- propylpyrimidine hydrochloride
(i) 2-[(2-Methylphenyl)amino]-6-propylpyrimidin-4-one
2-Methylthio-6-propylpyrimidin-4-one (Eur.J.Med.
Chem., (1988), 23, 53) (9.21 g, 0.05 m) and o-toluidine (5.5 g, 0.052 m) were mixed at room temperature and heated with stirring in an oil-bath at 170° for five hours.
Effluent gases were passed through a CHLOROS trap. The reaction mixture was cooled to produce a solid. Cold methanol was added and the insoluble solid collected, washed with cold methanol and dried to a light-grey solid (6.14 g) which was used immediately.
(ii) 4-Chloro-6-n-propyl-2-[(2-methylphenyl)amino]- pyrimidine
The product from Example 13 i) above (5.5 g,
0.0226 m) and phosphorous oxychloride (30 ml) were mixed at room temperature and heated at reflux temperature for 2% hours. The cooled solution was poured onto ice and the aqueous mixture neutralised with 6N. NaOH. The mixture was extracted with ethyl acetate, the organic extracts washed with water, dried and evaporated to give a brown oil which crystallised on scratching (5.5 g) and was used immediately.
(iii) 2-[(2-Methylphenyl)amino]-4-(N-methylphenylamino)- 6-n-propylpyrimidine hydrochloride.
The product from Example 13 ii) above (2.62 g,
0.01 m) and N-methylaniline (1.07 g, 0.01 m) were mixed at room temperature and heated, with stirring, in an oil-bath at 140° for two hours. The mixture, initially an oil, had virtually solidified by this time and was cooled, acetone added and the insoluble solid collected (2.12 g). This was crystallised from ethanol/diethyl ether to give the title compound (1.53 g) as its blue-white hydrochloride salt, m.p. = 170-172°.
C21H24N4. HCl.
Found: C 68.2, H 6.8, N 15.1, Cl- 9.6
Theory: C 68.4, H 6.8, N 15.2, Cl- 9.6
Example 14
2-r(4-Fluoro-2-methylphenyl)amino]-4-(N-methylphenyl- amino)-6-n-propylpyrimidine hydrochloride
(i) 2-[(4-Fluoro-2-methylphenyl)amino]-6-n-propyl
pyrimidin-4-one.
Substituting 4-fluoro-2-methylaniline (4.0 g,
0.032 M) for o-toluidine and using corresponding molar proportions of the other reagents in Example 13 (i) gave a crystalline solid which was collected, washed with cold methanol and dried, to give a grey solid (5.36 g). (ii) 4-Chloro-6-n-propyl-2-[(4-fluoro-2-methylphenyl)- amino]pyrimidine.
Substituting the product of Example 14 (i) above (5.2 g, 0.0199 m) for 2-[(2-methylphenyl)amino]-6-n- propylpyrimidin-4-one and using corresponding molar proportions of the other reagents in Example 13 (ii) gave a brown oil which crystallised on standing
(3.4 gms) which was used immediately. (iii) 2-[(4-Fluoro-2-methylphenyl)amino]-4-(N-methylphenylamino)-6-n-propylpyrimidine hydrochloride
4-Chloro-6-n-propyl-2-[(4-fluoro-2-methylphenyl)- amino]pyrimidine (3.0 g, 0.0107 m) and N-methylaniline (2.0 g, XS) were mixed at room temperature and heated, with stirring, in an oil-bath at 146° for 2 ½ hours.
The brown oil produced was cooled, acetone added and, on standing at 0° overnight, crystals separated which were collected, washed with acetone and dried (1.56 g). This solid was re-crystallised from ethanol/diethyl ether to give the title compound (0.92 g) as its colourless hydrochloride salt, m.p. = 165-167°.
C21H23FN4. HCl.
Found: C 65.1, H 6.3, N 14.5, Cl- 9.1
Requires: C 65.2, H 6.3, N 14.5, Cl- 9.2 Example 15
2-[(4-Fluoro-2-methylphenyl)amino]-4-(N-methyl-2-methyl- phenylamino)-6-n-propylpyrimidine hydrochloride
Substituting N-methyl-o-toluidine (0.664 g, 0.00549 m) for N-methylaniline and using corresponding molar
proportions of the other reagents in Example 14(iii) gave a red acetone solution after the heated reaction mixture had been allowed to cool. (N.B. In this example some white crystalline solid sublimed out of the heated reaction vessel during the reaction - this was shown by t.l.c. to be starting amine hydrochloride). The red acetone solution was evaporated to dryness and the residual oil dissolved in ethyl acetate. The red ethyl acetate solution was washed with aqueous Na2CO3, H2O, 2N.HCl and water, dried and evaporated to a buff solid (0.63 g). This was
crystallised from ethanol/ diethylether to give the title compound (0.42 g) as its pale-buff hydrochloride salt, m.p. = 170-172°.
C22H25FN4. HCl.
Found: C 65.5, H 6.4, N 13.8
Requires: C 65.9, H 6.5, N 14.0
Example 16 2-Amino-4-benzyl-6-r(2-methylphenyl)amino]pyrimidine
(i) 2-Amino-4-benzyl-6-chloropyrimidine.
2-Amino-6-benzylpyrimidin-4-one (J.Pharm.Sci. (1964), 53. 1317) (6.2 g, 0.0308 m) and phosphoryl chloride (40 ml) were mixed at room temperature and heated under reflux for three hours. The mixture was cooled, poured onto ice and the aqueous mixture basified with 2N.NaOH and extracted with chloroform. The chloroform extracts were combined, washed with water and brine, dried and evaporated to a green oily solid (2.25 g) which was used immediately.
(ii) 2-Amino-4-benzyl-6-[(2-methylphenyl)amino]pyrimidine The product from Example 16 (i) above (2.2 g,
0.01023 m) and o-toluidine (4.0 g, XS) were mixed at room temperature and heated with stirring in an oil-bath at 150° for three hours. The mixture was cooled, dissolved in methanol and acidified with 2N.HCl. The whole mixture was evaporated to dryness and the residue dissolved in distilled water (a little insoluble material was filtered off and discarded). The clear aqueous solution was basified with 2N NaOH to precipitate a light-buff solid (1.2 g). This was crystallised, first from acetone and finally from methanol/acetone to give the title compound (0.5 g), m.p. = 197-199°.
C18H18N4
Found: C 74.5, H 6.1, N 19.3
Requires: C 74.5, H 6.3, N 19.3
Example 17
6-Benzyl-2-[(2-methylphenyl)amino]-4-(N-methylphenylamino)- pyrimidine hydrochloride
(i) 6-Benzyl-2-[(2-methylphenyl)amino]pyrimidin-4-one
6-Benzyl-2-methylthiopyrimidin-4-one (Eur.J.Med.Chem. (1988), 23, 53) (8.37 g, 0.03608 m) and o-toluidine (4.06 g, 0.038 m) were mixed at room temperature and heated with stirring in an oil-bath at 170° for six hours, effluent gases being passed through a CHLOROS trap. The mixture was then cooled and treated at room temperature overnight with a mixture of methanol/acetone, 1:1. A yellow solid was produced which was collected, washed with acetone and dried (6.1 g). A portion was re-crystallised from methanol to give the title compound as an off-white solid, m.p. = 153-155°.
C18H17N3O
Found: C 74.4, H 5.8, N 14.3
Requires: C 74.2, H 5.9, N 14.4
(ii) 4-Benzyl-6-chloro-2-[(2-methylphenyl)amino]pyrimidine
The product of Example 17 (i) above (5.3 g, 0.0182 m) and phosphoryl chloride (30 ml) were mixed at room
temperature and heated under reflux for 2% hours. The orange solution was then cooled, poured onto ice and the aqueous mixture neutralised with 40% NaOH. The mixture was extracted with ethyl acetate and the combined organic extracts washed, dried and evaporated to a yellow oil
(5.1 g) which was used immediately without further
purification.
(iii) 6-Benzyl-2-[(2-methylphenyl)amino]-4-(N-methylphenylamino)pyrimidine hydrochloride
The product from Example 17 (ii) above (5.1 g,
0.0165 m) and N-methylaniline (3.53 g, 0.033 m) were mixed at room temperature and heated with stirring in an oil-bath at 150° for 2½ hours. The mixture was cooled and acetone added at ~70°. The mixture was boiled to give a clear solution and cooled when a solid crystallised which was collected, washed with acetone and dried. The material was re-crystallised twice from ethanol/diethyl ether to give the title compound (2.18 g) as its blue-white hydrochloride salt, m.p. = 183-185°.
C25H24N4. HCl.
Found: C 71.8, H 6.1, N 13.3, Cl- 8.3
Requires: C 72.0, H 6.0, N 13.4, Cl- 8.5 Example 18
5.6-Dimethyl-2-[(2-methylphenyl)amino]-4-(phenylamino)-pyrimidine hydrochloride (i) 5,6-Dimethyl-2-[(2-methylphenyl)amino]pyrimidin-4-one
5,6-Dimethyl-2-methylthiopyrimidin-4-one (Eur.J.Med. Chem. (1988), 22, 53) (24.0 g, 0.14 m) and o-toluidine (30 ml) were stirred together under nitrogen at 200-220° for 12 hours with effluent gases being passed through a CHLOROS trap. After cooling the reaction mixture was triturated with pentane, the insoluble solid filtered off and crystallised from methanol/ethyl acetate to give the title compound (23.1 g), m.p. = 194-5°.
(ii) 4-Chloro-5,6-dimethyl-2-[(2-methylphenyl)amino pyrimidine
The product of Example 18 (i) above (13.0 g, 0.057 m) and phosphorous oxychloride (200 ml) were heated together at reflux temperature for two hours. The POCl3 was distilled off and ice added carefully to the residue which was then basified with sodium hydroxide. The aqueous mixture was extracted with chloroform and the combined organic extracts dried and evaporated to dryness. The residue was chromatographed on silica gel in chloroform and appropriate fractions combined, evaporated and the residue triturated with pentane to yield the title
compound as a solid (8.5 g), m.p. = 95-98°.
(iii) 5, 6-Dimethyl-2-[(2-methylphenyl)amino]-4-(phenyl- amino)pyrimidine hydrochloride
The product of Example 18 (ii) above (2.5 g, 0.01 m) and aniline (0.93 g, 0.01 m) were heated at reflux
temperature in dry tetrahydrofuran (30 ml) for nine hours.
The solid which crystallised out on cooling was filtered off and re-crystallised from methanol/isopropanol/diethyl ether to yield the title compound (2.7 g) as its
hydrochloride salt, m.p. = 257-259°.
C19H20N4. HCl.
Found: C 67.0, H 6.2, N 16.4, Cl- 10.4
Requires: C 67.1, H 6.1, N 16.4, Cl- 10.4
Example 19
5 ,6-Dimethyl-2-[(2-methylphenyl)amino]-4-(N-methyl-2-methylphenyl amino)pyrimidine hydrochloride
A mixture of 4-chloro-5,6-dimethyl-2-[(2-methyl- phenyl)amino] pyrimidine (1.17 g, 0.005 m) and N-methyl- o-toluidine (6.0 ml) were heated together at 140° for six hours. After cooling ether was added to remove excess N-methyl-o-toluidine. Decanting off the ether and crystallisation of the solid residue from isopropanol/ ether gave the title compound (0.7 g) as its hydrochloride salt, m.p. = 192-194°. C21H24N4. HCl.
Found: C 68.1, H 6.8, N 15.0
Requires: C 68.4, H 6.8, N 15.2 Example 20
5,6-Dimethyl-2-r(2-methylphenyl)amino]-4-(N-methyl¬phenylamino)pyrimidine hydrochloride A mixture of 4-chloro-5,6-dimethyl-2-[(2-methyl- phenyl)amino]pyrimidine (2.5 g, 0.01 m) and
N-methylaniline (1.07 g, 0.01 m) in dry tetrahydrofuran (30 ml) was heated at reflux temperature for six hours.
After cooling, ether was added to precipitate a solid which was collected, washed with ether and crystallised from isopropanol/ether to yield the title compound
(1.61 g) as its hydrochloride salt, m.p. = 199-200°.
C20H22N4. HCl.
Found: C 67.8, H 6.6, N 15.3, Cl- 9.8
Requires: C 67.8, H 6.5, N 15.8, Cl- 10.0
Example 21
5-Methyl-6-n-propyl-2-[(2-methyl)phenyl)aminol-4-(N-methyl-2-methyl phenylamino)pyrimidine hydrochloride
(i) 2-[(2-Methylphenyl)amino]-5-methyl-6-n-propyl- pyrimidin-4-one
2-Methylthio-5-methyl-6-n-propylpyrimidin-4-one (C.A. 84. P164836n) (16.0 g, 0.08 m) and o-toluidine (30 ml) were heated together at 200° (oil-bath temp) for six hours. After cooling, the mixture was triturated with pentane and the pentane decanted. The residual solid was crystallised from methanol/isopropylacetate to yield the title compound (10.5 g), m.p. = 192-194°.
(ii) 4-Chloro-5-methyl-6-n-propyl-2-[(2-methylphenyl)- amino]pyrimidine
The product of Example 21 (i) above and phosphorous oxychloride (50 ml) were heated together under reflux for two hours. The POCl3 was distilled off and ice carefully added to the residue. The aqueous mixture was basified with sodium hydroxide and extracted with chloroform. The combined chloroform extracts were concentrated to a low volome and chromatographed on silica gel with chloroform as eluent. Appropriate fractions were combined and evaporated to an oil (11.0 g) which was used immediately below. (iii) 5-Methyl-6-n-propyl-2-[(2-methylphenyl)amino]-4- (N-methyl-2-methylphenylamino)pyrimidine hydrochloride
The product of Example 21 (ii) above (5.5 g, 0.02 m) and N-methyl-o-toluidine (2.4 g, 0.02 m) in
tetrahydrofuran (45 ml) were heated together at reflux temperature for three hours, cooled and concentrated to a low volume. Ether was added and the precipitated solid collected, washed with ether and re-crystallised twice from isopropylacetate to give the title compound (1.05 g) as its hydrochloride salt, m.p. = 170-171°.
C23H28N4. HCl.
Found: C 69.6, H 7.4, N 13.9, Cl- 8.8
Requires: C 69.6, H 7.4, N 14.1, Cl- 8.9 Example 22
5-Methyl-6-n-propyl-2- [ (2-methylphenyl) amino] -4- (N-methylphenylamino) pyrimidine hydrochloride
Substituting N-methylaniline (2.14 g, 0.02 m) and using corresponding molar proportions of the other
reagents in Example 21(iii) gave a crystalline solid directly from the tetrahydrofuran reaction mixture.
This was collected and washed with ether to give the title compound (4.5 g) as its hydrochloride salt,
m.p. 178-179°.
C22H26N4. HCl.
Found: C 69.3, H 7.3, N 14.6, Cl- 9.2
Requires: C 69.0, H 7.1, N 14.6, Cl- 9.3
Example 23
2-[(2-Methylphenyl)amino]-4-(N-methylphenylamino)-5,6,7,8-tetrahydroguinazoline hydrochloride !SK&F 99119!
(i) 2-Thioxo-5,6,7,8-tetrahydroquinazolin-4-one.
Sodium (8.5 g, 0.37 mol) was dissolved in absolute ethanol (300 mL) and treated with ethyl-2-oxocyclo- hexanecarboxylate (40 g, 0.186 mol) and thiourea (14.2 g, 0.186 mol) and refluxed for 4 hours. The solvent was removed in vacuo and the residual solid dissolved in water and made acidic with acetic acid. The solid was
collected, washed with water and dried to give the title compound (32 g), m.p. = 305-308°. (ii) 2-Methylthio-5,6,7,8-tetrahydroquinazolin-4-one.
2-Thioxo-5,6,7,8-tetrahydroquinazolin-4-one (18.2 g, 0.1 mol) was added to a solution of sodium hydroxide (4.4 g, 0.11 mol) in water (25 ml). Ethanol (100 ml) was introduced followed by methyl iodide (15.6 g, 0.11 mol) and the final solution stirred at 60° for two hours. The suspension was cooled and filtered and the solid washed with diethyl ether to give the title compound (17.6 g), m.p. = 215-219°.
(iii) 2-[(2-Methylphenyl)amino]-5,6,7,8-tetrahydro- quinazolin-4-one 2-Methylthio-5,6,7,8-tetrahydroquinazolin-4-one
(16.8 g, 0.085 mol) and o-toluidine (50 ml) were heated at 220° for 24 hours and allowed to cool. The effluent gases from this reaction were passed through a CHLOROS trap. The mixture was treated with 40-60 petroleum spirits and filtered and the solid collected and
recrystallised from dimethyl sulphoxide/water to give the title compound (16.6 g), m.p. = 253-257°.
(iv) 4-Chloro-2-[(2-methylphenyl)amino]-5,6,7,8- tetrahydroquinazoline.
2-[(2-Methylphenyl)amino]-5,6,7,8-tetrahydro- quinazolin-4-one (16 g, 0.063 mol) and redistilled phosphorous oxychloride (50 ml) were heated to reflux temperature for three hours, allowed to cool and
evaporated to dryness. The residual oil was treated with ice-water and extracted with chloroform. The combined organic extracts were washed with sodium bicarbonate solution, water, dried and filtered. The residue after evaporation was chromatographed on silica gel using chloroform as eluent, the appropriate fractions combined and evaporated to give a solid which was
triturated with 60-80 petroleum spirits to give the title compound (6.1 g), m.p. = 116-124°.
(v) 2-[(2-Methylphenyl)amino]-4-(N-methylphenyl)amino- 5,6,7,8-tetrahydroquinazoline hydrochloride.
4-Chloro-2-[(2-methylphenyl)amino]-5,6,7,8-tetra- hydroquinazoline (2.73 g, 0.01 mol) and N-methyl aniline (1.07 g, 0.01 mol) were heated to reflux temperature in dioxane (50 ml) for sixteen hours and allowed to cool.
The solvent was removed in vacuo and the residue dissolved in petroleum spirits and filtered. The solid was
recrystallised from ethanol/diethyl ether, filtered and the solid washed with ether to give the title compound (0.98 g) , m.p. = 222-226°.
C22H24N4 .HCl .0.7H2O .0.1EtOH
Found: C 66.70, H 6.50, N 13.86
Requires: C 67.14, H 6.59, N 14.10
Example 24
2-[(2-Methylphenyl)amino]-4-(N-methyl-2-methylphenylamino)- 5,6,7,8-tetrahydroquinazoline hydrochloride. !SK&F 99118!
Substituting N-methyl-o-toluidine (1.21 g, 0.01 mol) for N-methyl aniline and using corresponding molar
proportions of other reagents as in Example 23 above gave a mixture which was heated to reflux temperature for sixteen hours and allowed to cool. The solvent was removed in vacuo and the residual oil dissolved in chloroform, washed twice with sodium bicarbonate solution, water, dried and filtered. The oil obtained from
evaporation of the solvent was chromatographed on silica gel using chloroform as eluent, the appropriate fractions combined and evaporated to give a pale orange oil. This was dissolved in ethanolic HCl and the solvent removed to give an oil which was triturated with diethyl/ether to give a solid. This was recrystallised from ethanol/diethyl ether, filtered and washed with ether to give the title compound (0.42 g) m.p. = 227-228°.
C23H26N4 .HCl .0.7H2O
Found: C 67.54, H 6.58, N 13.74, Cl- 8.80
Requires: C 67.89, H 6.86, N 13.37, Cl- 8.71 Example 25
2-[(2-Methylphenyl)amino)-4-(N-methylphenylamino)-cyclopenta[d]pyrimidine hydrochloride !SK&F 99149! (i) 2-Methylthiocyclopenta[d]pyrimidin-4-one
Ethyl-2-oxocyclopentanecarboxylate (62.4 g, 0.4 mol) and S-methylthiouronium sulphate (111.2 g, 0.4 mol) were added to a solution of potassium hydroxide (36 g, 0.64 mol) in methanol (500 ml) and stirred at room temperature for two hours. This was poured into water (3000 ml) and extracted with chloroform. The combined extracts were dried, filtered and the solvent evaporated to give a solid which was triturated with diethyl ether and filtered to give the title compound (11.2 g) m.p. = 210-213°. (ii) 2-[(2-Methylphenyl)amino]cyclopenta[d]pyrimidin-4-one.
2-Methylthiocyclopenta[d]pyrimidin-4-one (5.1 g,
0.028 mol) and o-toluidine 920 ml) were heated to 220° for sixteen hours and allowed to cool to give an oil. The effluent gases from this reaction were passed through a CHLOROS trap. This was triturated with 40-60 petroleum spirits and a solid filtered off and washed with more solvent to give the title compound (6.8 g),
m.p. = 208-213°.
(iii) 4-Chloro-2-[(2-methylphenyl)amino]cyclopenta[d]- pyrimidine. 2-[(2-Methylphenyl)amino]cyclopenta[d]pyrimidin-4-one (6.7 g, 0.028 mol) and phosphorus oxychloride (70 ml) were heated together under reflux for three hours and then evaporated to dryness. The residual oil was added
carefully to ice/ammonia solution and extracted with chloroform. The combined extracts were washed with sodium bicarbonate solution, water, filtered and dried to give an oil. This was chromatographed on silica gel using chloroform as eluent and the appropriate fractions were combined, evaporated and the residue triturated with 40-60 petroleum spirits to give the title compound (2.1 g), m.p. 135-142°.
(iv) 2-[(2-Methylphenyl)amino)]-4-(N-methylphenyl)amino- cyclopenta[d]pyrimidine hydrochloride.
4-Chloro-2-[(2-methylphenyl)amino]cyclopenta[d]- pyrimidine (1.0 g, 0.0038 mol) and N-methyl aniline
(0.49 g, 0.0046 mol) were refluxed in dry dioxane (60 ml) for sixteen hours. The mixture was evaporated to dryness and the resultant solid recrystallised from ethanol/diethyl ether, filtered and washed with ether to give the title compound (0.72 g), m.p = 210-218° (dec).
C21H22N4 .HCl .H2O
Found: C 65.28, H 6.25, N 14.33
Requires: C 65.53, H 6.55, N 14.55
Example 26
2-[(2-Methylphenyl)amino)-4-(N-methyl-2-methylphenyl-amino) cyclopenta [d]pyrimidine hydrochloride. !SK&F 99148!
4-Chloro-2-[(2-methylphenyl)amino]cyclopenta[d]- pyrimidine (1.0 g, 0.0038 mol) and N-methyl-o-toluidine (0.59 g, 0.0046 mol) were refluxed in dry dioxane (60 ml) for sixteen hours. The mixture was evaporated to dryness and the resultant solid triturated with diethyl ether to give a solid which was recrystallised from ethanol/diethyl ether, filtered and washed with diethyl ether to give the title compound (0.58 g), m.p. = 210-214°.
C22H24N4 .HCl .0.8H2O
Found: C 66.55, H 6.42, N 14.22
Requires: C 66.83, H 6.78, N 14.17
Example 27
2-Amino-4-(2-methylphenylamino)-5-methyl-6- (methoxymethyl)pyrimidine
(i) Ethyl 2-methyl-3-oxo-4-methoxybutyrate
Zinc (36.12 g, 0.55 mol), methoxyacetonitrile
(26.18 g, 0.37 mol), benzene (370 ml) and a small amount of mercuric chloride were heated to reflux under nitrogen. A solution of ethyl 2-bromopropionate (100 g, 0.55 mol) in benzene was added dropwise over 2.5 h, then reflux
continued for a further hour before cooling to room temperature. 10% Aqueous sulphuric acid (650 ml) was added, and the layers separated. The aqueous was further extracted with ether (2 x 250 ml), and the combined organic layers washed with water and aqueous NaHCO3, then dried and evaporated. Distillation gave the title
compound as an oil (36.53 g), b.p. 111°/12mm.
(ii) 2-Amino-5-methyl-6-methoxymethylpyrimidine-4-one
Guanidinium carbonate (8.8 g, 49 mmol) and ethyl 2- methyl-3-oxo-4-methoxybutyrate (17.0 g, 98 mmol) in ethanol (200 ml) were heated under reflux for 4.5 hours. The solvent was evaporated and the residue treated with ice-cold water (100 ml) and acidified to pH 5 with glacial acetic acid. The solid which precipitated was filtered off, washed with a small amount of cold water and dried to give the title compound (14.47 g), m.p. 237-239°C.
(iii) 2-Amino-4-chloro-5-methyl-6-methoxymethylpyrimidine
2-Amino-5-methyl-6-methoxymethylpyrimidine-4-one (7.0 g, 41 mmol) and phosphoryl chloride (21 ml) were heated at reflux for 70 min. Excess phosphoryl chloride was evaporated off and the residue treated with ice (100 ml), then brought to pH 8 with ammonium hydroxide. The yellow solid was filtered off, and the filtrate reduced in volume to obtain further crops. The combined solids were washed with cold water and dried to give the title
compound (5.75 g), m.p. 201-203°C.
(iv) 2-Amino-4-(2-methylphenylamino)-5-methyl-6- methoxymethylpyrimidine
2-Amino-4-chloro-5-methyl-6-methoxymethylpyrimidine (5.65 g, 30 mmol) and o-toluidine (7.06 g, 66 mmol) in n- butanol (100 ml) were heated under reflux for 4.5 h. The solvent was evaporated, the residue triturated with ether, and the solid filtered off and dissolved in a small volume of water. The solution was raised to pH 8 with ammonium hydroxide and extracted repeatedly with chloroform. The combined extracts were dried and evaporated, and the residue crystallised from chloroform/ether to give the title compound (1.18 g), m.p. 148-149°C.
C14H18N4O .0.25H2O
Found C 64.24, H 6.90, N 21.23
Requires C 63.97, H 7.09, N 21.31 Example 28
2-(2-Methylphenylamino)-4-(N-methylphenylamino)-6-aminopyrimidine hydrochloride (i) 6-Amino-2-[(2-methylphenyl)amino]pyrimidin-4-one
6-Amino-2-(nitroamino)pyrimidin-4-one (4.28 g, 25 mmol) and o-toluidine (6.42 g, 60 mmol) were added to dry pyridine (50 ml), and the mixture heated to reflux for 48 hours. The pyridine was evaporated in vacuo, and the oily residue boiled with ethyl acetate, then allowed to cool. The resulting solid was mainly unreacted starting
material, and was filtered off and discarded (1.46 g). The filtrate was extracted with aqueous sodium hydroxide, and the extracts neutralised with hydrochloric acid and re-extracted with ethyl acetate. Drying and evaporation of the organic extracts, and trituration with ether gave the title compound (2.3 g, 42%), m.p. 142-147°C.
(ii) 4-Amino-6-chloro-2[(2-methylphenyl)amino]pyrimidine
6-Amino-2-[(2-methylphenyl)amino]ρyrimidin-4-one
(2.0 g, 9.26 mmol) and phosphoryl chloride (20 ml, excess) were heated to reflux for 1 hour, then the solution was cooled and poured onto ice. The dark oil was extracted into ethyl acetate, then the aqueous layer was neutralised with sodium hydroxide and re-extracted with ethyl acetate. The combined organic extracts were washed with aqueous sodium carbonate, water and brine, dried and evaporated to a brown tar (1.2 g), which was used immediately without further purification. (iii) 2-(2-Methylphenylamino)-4-(N-methylphenylamino)-6-aminopyrimidine hydrochloride
A mixture of 6-amino-4-chloro-2-[(2-methylphenyl)- amino]pyrimidine (1.2 g, 5.1 mmol) and N-methylaniline (3.0 g, excess) was heated to 170°C for 4 hours, then allowed to cool. The tarry product was washed with 1:1 ether/pet. ether, then chromatographed (silica, 0-1% MeOH in CH2Cl2). Product fractions were evaporated and converted to the hydrochloride, which crystallised from ethanol/ether (0.08g), m.p. 218-220°C. A second crop (0.18 g) was obtained from the mother liquors.
C18H19N5
Found C 63.00, H 5.99, N 20.20
Requires C 63.24, H 5.90, N 20.49
Example 29 2-(2-Methylphenylamino)-4-(N-methylphenylamino)-5-propyl- 6-methylpyrimidine hydrochloride
(i) Ethyl 2-propyl-3-oxobutyrate To a solution of ethyl acetoacetate (39.04 g, 0.3 mol) and 1, 8-diazabicyclo [5.4.0]undec-7-ene (45.67 g, 0.3 mol) in dry benzene (500 ml) was added a solution of 1- iodopropane (51.0 g, 0.3 mol) in dry benzene (200 ml).
The mixture was stirred for 3h, then the solid which precipitated was filtered off, washed with water, dried and evaporated in vacuo. The resulting brown oil was distilled twice under reduced pressure to give the title compound as a clear oil, yield 18.06 g, b.p. 80°C/18 mm. (ii) 6-Methyl-2-thioxo-2-oxo-5-propylpyrimidine
Sodium (4.14 g, 0.18 mol) was dissolved in ethanol (150 ml), and a solution of ethyl 2-propyl-3-oxobutyrate (15.46 g, 0.09 mol) in ethanol was added, followed by thiourea (6.48 g, 0.09 mol). The mixture was heated under reflux for 4h, then the solvent was evaporated. The residue was dissolved in water and acidified to pH 4 with glacial acetic acid. The white solid which
precipitated was filtered off, washed with water and dried to give the title compound (8.97 g), m.p. 207-208°C. (iii) 2-Methylthio-5-propyl-6-methylpyrimidin-4-one
To a solution of sodium hydroxide (2.2 g, 55 mmol) in water (75 ml) was added 6-methyl-2-thioxo-4-oxo-5- piropylpyrimidine (9.46 g, 50 mmol), followed by
iodomethane (7.81 g, 55 mmol). The mixture was heated under reflux for 3h, then stirred at room temp, for 16h. Excess iodomethane was evaporated off, and the solution acidified to pH 4 with glacial acetic acid. The white solid which precipitated was filtered off, washed with water and dried to give the title compound (9.88 g), m.p. 178°C.
(iv) 2-(2-Methylphenylamino)-5-propyl-6-methylpyrimidin-4- one
2-Methylthio-5-propyl-6-methylρyrimidin-4-one (9.76 g,
49.2 mmol) and 2-methylaniline (37 ml, 350 mmol) were heated with stirring at 170°C for 17h. Excess toluidine was distilled off in vacuo, and the residue boiled with ethanol to give a white solid, which was filtered off, washed and dried to give the title compound (9.35 g), m.p. 223°C.
(v) 2-(2-Methylphenylamino)-4-chloro-5-propyl-6- methylpyrimidine
2-(2-Methylphenylamino)-5-ρropyl-6-methylpyrimidin-4- one (4.0 g, 15.5 mmol) and phosphoryl chloride (12 ml, excess) were heated under reflux for 3h. Excess
phosphoryl chloride was evaporated off, and the residue treated with ice-water. The mixture was extracted with chloroform, washed with aqueous sodium bicarbonate, dried and evaporated to give the product as a yellow oil which crystallised on standing; yield 3.68 g, m.p. 94-96°C.
(vi) 2-(2-Methylphenylamino)-4-(N-methylphenylamino)-5- propyl-6-methylpyrimidine hydrochloride
A solution of 2-(2-methylphenylamino)-4-chloro-5- propyl-6-methylpyrimidine (1.8 g, 6.53 mmol) and N- methylaniline (0.84 g, 7.84 mmol) in dioxan (20 ml) was heated under reflux for 17h. The solvent was evaporated, then the residue was boiled with ethanol and filtered hot. On allowing to cool, the filtrate deposited a yellow solid, which was filtered off and recrystallised from ethanol; yield 0.73 g, m.p. 258°C.
C22H26N4 .HCl
Found C 68.88, H 7.22, N 14.60
Requires C 69.00, H 7.11, N 14.63
Example 30
2-(2-Methylphenylamino)-4-(N-methylphenylamino)-5-(2-benzyloxyethyl)-6-methylpyrimidine
(i) 6-Methyl-2-thioxo-4-oxo-5-(2-hydroxyethyl)pyrimidine
2-Acetylbutyrolactone (64 g, 0.5 mol) and thiourea (38 g, 0.5 mol) were added to a solution of sodium (23 g, 1.0 mol) in absolute ethanol (600 ml). The mixture was stirred under reflux for 4 hours, then allowed to stand overnight. The solvent was removed by evaporation, the residual solid was dissolved in water (500 ml), and the solution acidified with acetic acid. The deposited solid was filtered off, washed with water and dried; yield
34.8 g (40%), m.p. 264-272°C.
(ii) 6-Methyl-2-methylthio-4-oxo-5-(2-hydroxyethyl)-pyrimidine
A suspension of 6-methyl-2-thioxo-4-oxo-5-(2- hydroxyethyl) pyrimidine (10.0 g, 0.053 mol) in absolute ethanol (100 ml) was added to a solution of sodium
hydroxide (2.4 g, 0.104 mol) in water (50 ml). Methyl iodide (8.4 g, 0.059 mol) was added and the mixture was stirred under reflux for 4 hours, then allowed to cool. The deposited solid was filtered off, washed with water and dried; yield 6.0 g (60%), m.p. 186-190°C.
(iii) 6-Methyl-2-methylthio-4-oxo-5-(2-benzyloxy- ethyl)pyrimidine
6-Methyl-2-methylthio-4-oxo-5-(2-hydroxyethyl)- pyrimidine (32.2 g, 0.186 mol) was added in portions to a stirred suspension of pet. ether-washed 60% sodium hydride (17.5 g, 0.437 mol) in dry dimethylformamide (400 ml) at a temperature of 30-40°C. The mixture was stirred for 30 min at this temperature, then a solution of benzyl bromide (32.9 g, 0.192 mol) in dimethylformamide (50 ml) was added dropwise over 10 min to the stirred mixture. The mixture was stirred for 1 hour at room temperature, then poured into a solution of water (500 ml) containing ammonium chloride, and allowed to stand. The deposited solid was filtered off, dried, and recrystallized from ethyl acetate. The product was collected as a white solid;
yield 29.5 g (57%), m.p.-139-144°C. (iv) 6-Methyl-2-[(2-methylphenyl)amino]-4-oxo-5-(2- benzyloxyethyl)pyrimdine
A mixture of 6-methyl-2-methylthio-4-oxo-5- (2- benzyloxyethyl) pyrimidine (29 g, 0.104 mol) and o- toluidine (150 ml, excess) was stirred at 200° C for 16 hours, then allowed to stand overnight. The solidified residue was triturated with diethyl ether to obtain the title compound; yield 29.9 g (82%), m.p. 162-168°C.
(v) 6-Methyl-2-[(2-methylphenyl)amino]-4-chloro-5-(2- benzyloxyethyl)pyrimidine
A mixture of 6-methyl-2-[(2-methylphenyl)amino]-4-oxo- 5-(2-benzyloxyethyl)pyrimidine (25 g, 0.071 mol) and phosphoryl chloride (150 ml, excess) was stirred under reflux for 1 hour, the excess phosphoryl chloride removed by evaporation, and the residual oil treated with an excess of ice/water. The crude product was extracted with chloroform, the organic layer washed with saturated sodium bicarbonate and water, dried over MgSO4 and the solvent evaporated, the product being a pale yellow viscous oil; yield 14 g. (vi) 6-Methyl-2-[(2-Methylphenyl)amino]-4-(N-methylphenylamino)-5-(2-benzyloxyethyl)pyrimidine
A mixture of 6-methyl-2-[(2-methylphenylamino]-4- chloro-5-(2-benzyloxyethyl)pyrimidine (1.0 g, 2.72 mmol) and an excess of N-methylaniline (3 ml) was stirred and heated at 180-200°C for 2 hours. After cooling, the crude oil was purified by chromatography (silica gel,
chloroform). A further 2 columns were required to obtain the product as a viscous oil; yield 200 mg. C28H30N4O .0.2CHCl3 .0.1H2O
Calc: C 72.95, H 6.60, N 12.06
Found: C 73.05, H 6.62, N 12.03 Example 31
2-(2-Methylphenylamino)-4-(N-methyl-2-methylphenylamino)-5-(2-benzyloxyethyl)-6-methylpyrimidine (i) 6-Methyl-2-[(2-methylphenyl)amino]-4-[N-methyl-(2-methylphenyl)amino]-5-(2-benzyloxyethyl)pyrimidine
A mixture of 6-methyl-2-[(2-methylphenyl)amino]-4-chloro-5-(2-benzyloxyethyl)pyrimidine (2.0 g, 0.0544 mol) and N-methyl-o-toluidine (5 ml, excess) was stirred at
200°C for 2 hours. After cooling, the crude residue was purified by silica gel chromatography, eluted with CHCI3.
A second column was required to obtain the product as a pale orange-coloured oil; yield 0.2 g.
C29H32N4O .0.3CHCl3 .0.1H2O
Calc: C 71.79, H 6.68, N 11.43
Found: C 71.75, H 6.70, N 11.53
Example 32
2-(2-Methylρhenylamino)-4-(N-methylphenylamino)-5-(2-hydroxyethyl)-6-methylpyrimidine
6-Methyl-2-[(2-methylphenyl)amino]-4-(N- methylphenylamino)-5-(2-benzyloxyethyl)pyrimidine (2.3 g, 5.25 mmol) was mixed with 10% palladium on carbon in absolute ethanol (100 ml) and hydrogenated at 50 psi and 50°C for 12 hours. The product obtained by evaporation of the filtrate was crystallized from ethanol/diethyl ether and finally purified by silica gel chromatography, eluted with CHCl3/MeOH (25:1). The product was obtained as a pale grey solid; yield 0.4 g (22%), m.p. 98-100°C.
C21H24N4O
Calc: C 72.39, H 6.94, N 16.08
Found: C 72.11, H 7.04, N 15.90 Example 33
2-(2-Methylphenylamino)-4-(N-methyl-2-methylphenylamino(- 5-(2-hydroxyethyl)-6-methylpyrimidine A mixture of 6-methyl-2-[(2-methylphenylamino]-4-(N- methyl-2-methylphenylamino)-5-(2-benzyloxyethyl)pyrimidine (0.7 g, 1.55 mmol) and 10% palladium on carbon catalyst (0.35 g) in absolute ethanol (50 ml) was hydrogenated at 50 psi and 50°C for 6 hours, followed by further reduction for 4 hours with fresh catalyst. After separation of the catalyst the filtrate was chromatographed (silica gel, CHCl3/MeOH (25:1)). Product fractions were evaporated and triturated with pet. ether to give the title compound as a white crystalline solid; yield 0.13 g (23%), m.p. 161- 163°C.
C22H26N4O .0.3H2O
Calc: C 71.82, H 7.28, N 15.32
Found: C 71.57, H 7.11, N 14.93 Example 34
2- (2-Methylphenylamino) -4- (N-methylphenylamino) -6-(benzyloxymethyl) pyrimidine hydrochloride
(i) 2-Thioxo-6-(benzyloxymethyl)pyrimid-4-one
To a solution of sodium (5.26 g, 0.224 mol) in ethanol (250 ml) was added thiourea (8.69 g, 0.114 mol) and ethyl 4-benzyloxyacetoacetate (27.0 g, 0.114 mol) and the mixture heated under reflux for 3 hours. The solvent was evaporated off and water (300 ml) added, followed
by glacial acetic acid to pH 4. The resulting solid was filtered, washed and dried to give the title compound (22.12 g), m.p. 182-185°C.
(ii) 2-Methylthio-6-(benzyloxymethyl)pyrimid-4-one
To a solution of sodium hydroxide (2.3 g, 0.0581 mol) in water (15 ml) was added 2-thioxo-6-(benzyloxymethyl)- pyrimid-4-one in ethanol (150 ml) and iodomethane (8.25 g, 0.0581 mol). The mixture was stirred at room temperature for 16 hours. The resulting solid was filtered off, washed and dried to yield the title compound (9.20 g), m.p. 156-158°C.
(iii) 2-(2-Methylphenylamino)-6-(benzyloxymethyl)-pyrimid-4-one 2-Methylthio-6-(benzyloxymethyl)pyrimid-4-one (13.0 g, 0.065 mol) and o-toluidine (20.856 g, 0.195 mol) were heated with stirring under nitrogen at 200°C for 16 hours. After cooling, the mixture was triturated with ether to give a brown solid which was filtered off, washed and dried (11.30 g) m.p. 95-98°C. (iv) 2-(2-Methylphenylamino)-4-chloro-6-(benzyloxymethyl)pyrimidine.
2-(2-Methylphenylamino)-6-(benzyloxy-methyl)ρyrimid-4- one (3.14 g, 0.0098 mol) and phosphoryl chloride (30 ml, excess) were heated with stirring under reflux for 1 hour. The phosphoryl chloride was evaporated off and the residue poured onto iced water, neutralised and extracted with chloroform. The combined extracts were dried, filtered and evaporated to an oil. This was purified by flash chromatography (silica, dichloromethane / 40-60 petroleum ether) to give the title compound as a yellow oil
(1.33 g). (v) 2-(2-Methylphenylamino)-4-(N-methylphenylamino)-6- (benzyloxymethyl)pyrimidine hydrochloride.
2-(2-Methylphenylamino)-4-chloro-6- (benzyloxymethyl)pyrimidine (1.33 g, 0.0039 mol) and N- methylaniline (0.5 g, 0.0047 mol) in 1,4-dioxane were stirred and heated under reflux for 16 hours. The solvent was evaporated off and the residue triturated with ether to give a white solid. This was filtered off,
recrystallised from methanol/ether and dried to give the title compound (0.6 g), m.p. 180°C.
C26H26N4O .HCl .0.32H2O .0.1C2H5OH.
Found: C 69.04, H 6.09, N 12.28
Requires:C 68.80, H 6.22, N 12.26 Example 35
2-(2-Methylphenylamino)-4-(N-methylphenylamino)-6-methoxymethylpyrimidine hydrochloride (i) 2-Methylthio-6-(methoxymethyl)pyrimid-4-one To a solution of potassium hydroxide (92.1 g, 1.642 mol) in methanol (2500 ml) was added methyl 4- methoxyacetoacetate (150 g, 1.026 mol) and 2-methyl-2- thiopseudourea sulphate (285.6 g, 1.026 mol). The mixture was stirred at room temperature for 3 hours. The solvent was evaporated off and water (500 ml) added, followed by glacial acetic acid to pH 4. The resulting solid was filtered off, washed and dried to yield the title compound (166.02 g), m.p. 184-186°C.
(ii) 2-(2-Methylphenylamino)-6-(methoxymethyl)pyrimid-4-one
2-Methylthio-6-methoxymethylpyrimid-4-one (80 g, 0.43 mol) and o-toluidine (138.55 g, 1.29 mol) were heated to 200°C under nitrogen with stirring for 16 hours. On cooling the product crystallised out and was filtered off, washed with ether and dried to yield the title compound (86.12 g), m.p. 140-145°C. (iii) 2-(2-Methylphenylamino)-4-chloro-6- (methoxymethyl)pyrimidine.
2-(2-Methylphenylamino)-6-methoxymethylpyrimid-4-one (86.0 g, 0.351 mol) and phosphoryl chloride (500 ml, excess) were heated with stirring under reflux for 1 hour. The excess phosphoryl chloride was evaporated off and the residue poured onto iced water, neutralised and extracted using chloroform (x3). The combined extracts were dried, filtered and evaporated to an oil. This was purified by flash chromatography (silica, dichloromethane / 40-60 petroleum ether) to give the title compound as a yellow oil (66.0 g). (iv) 2-(2-Methylphenylamino)-4-(N-methylphenylamino)-6- (methoxymethyl)pyrimidine hydrochloride.
2-(2-Methylphenylamino)-4-chloro-6- (methoxymethyl)pyrimidine (37.0 g, 0.141 mol) and N- methylaniline (18.10 g, 0.169 mol) in 1,4-dioxane were stirred and heated under reflux for 16 hours. On cooling, the product crystallised out and was filtered off, washed arid recrystallised from ethanol to give the title compound (19.36 g), m.p. 205-207°C.
C20H22N4O .HCl .0.21C2H5OH
Found: C 64.27, H 6.39, N 14.58
Requires:C 64.77, H 6.25, N 15.11 Example 36
2-(2-Methylphenylamino)-4-(N-methylphenylamino)-6- hydroxymethylpyrimidine To a solution of 2-(2-methylphenylamino)-4-(N- methylphenylamino)-6-(methoxymethyl)pyrimidine
hydrochloride (5.0 g, 0.0135 mol) in dichloromethane
(25 ml) was added dropwise boron tribromide (16.93 g, 0.0676 mol) in dichloromethane (5 ml), keeping the
temperature between -10 & 0°C. After a further hour at
0°C, the solution was poured on to iced water and basified to pH 14 using sodium hydroxide. The mixture was
extracted using dichloromethane (x3), and the combined extracts dried, filtered and evaporated. The residue was purified using flash chromatography (silica,
methanol/dichloromethane), triturated with ether and the resulting crystals filtered and dried to yield the title compound (3.94 g), m.p. 134-136°C. C19H20N4O .0.02C4H10O .0.07H2O
Found: C 70.75, H 6.34, N 17.14
Requires:C 71.23, H 6.29, N 17.49
Example 37
2- (2-Methylphenylamino) -4- (N-methylphenylamino) pyrimidine- 6-carboxaldehyde
To a stirring solution of oxalyl chloride (2.094 g, 0.0165 mol) in dichloromethane (50 ml) at -50°C was added dimethylsulphoxide (2.808 g, 0.036 mol) in dichloromethane (10 ml) dropwise, keeping the temperature below -50°C.
After 10 mins, a solution of 2-(2-methylphenylamino)-4-(N- methylphenylamino)-6-(hydroxymethyl)pyrimidine (5 g,
0.015 mol) in dichloromethane (50 ml) was added dropwise over 15 mins and stirred for a further 30 mins.
Triethylamine (3.821 g, 0.375 mol) was then added and the mixture allowed to warm to room temperature. Water (100 ml) was added and the mixture extracted with
dichloromethane (x2). The organic extracts were combined, dried, filtered and evaporated. The residue was purified by flash chromatography (silica, dichloromethane/methanol) then recrystallised from acetone-water to yield the title compound (2.1 g), m.p. 115-117°C.
C19H18N4O
Found: C 71.57, H 5.58, N 17.65
Requires:C 71.68, H 5.70, N 17.60 Example 38
2-(2-Methylphenylamino)-4-(N-methylphenylamino)-6- (methylthiomethyl)pyrimidine
(i) 2-(2-Methylphenylamino)-4-(N-methylphenylamino)-6- (bromomethyl)pyrimidine
To a stirred solution of 2-(2-methylphenylamino)-4-(N- methylphenylamino)-6-(hydroxymethyl)pyrimidine (5 g,
0.015 mol) in ether (100 ml) was added carbon tetrabromide (9.95 g, 0.03 mol) and triphenylphosphine (7.87 g, 0.03 mol). After 48 hours the ether was evaporated off and the residue purified by flash chromatography (silica,
dichloromethane) to give an oil. This was triturated with 40-60 petroleum ether and the resulting solid filtered off, washed and dried (4.20 g).
(ii) 2-(2-Methylphenylamino)-A-(N-methylphenylamino)-6- (methylthiomethyl)pyrimidine
Sodium thiomethoxide (1.097 g, 0.0157 mol) and 2-(2- methylphenylamino)-A-(N-methylphenylamino)-6- (bromomethyl)pyrimidine (3.0 g, 0.0078 mol) in methanol (150 ml) were stirred at room temperature for 16 hours. The solvent was evaporated off and the residue treated with water, then extracted with dichloromethane (x2).
The organic extracts were combined, dried, filtered and evaporated, and the residue crystallised from acetonitrile to yield the title compound (2.23 g), m.p. 137-140°C.
C20H22N4S
Found: C 68.69, H 6.32, N 16.08
Requires:C 68.54, H 6.33, N 15.99 Example 39
2- (2-Methylphenylamino) -4- (N-methylphenylamino) -5-methyl-6- (methoxymethyl) pyrimidine hydrochloride
(i) Ethyl-2-methyl-4-methoxyacetoacetate
To a stirring mixture of zinc (90.25 g, 1.38 mol) and mercuric chloride (trace) in dry benzene (1000 ml) under nitrogen was added methoxyacetonitrile (65.32 g, 0.92 mol). The reaction was heated to reflux for 15 minutes, then ethyl bromoproprionate in dry benzene (500 ml) added dropwise over 2.5 hours and refluxed for a further hour. After cooling, 10% sulphuric acid (1800 ml) was added and the mixture extracted with ether (x3). The extracts were washed with dilute sodium bicarbonate, dried, filtered and evaporated to an oil. Distillation under reduced
pressure gave the title compound (91.2 g), b.p. 100- 116°C/9mm.
(ii) 2-Methylthio-5-methyl-6-(methoxymethyl)pyrimid-4-one
To a solution of potassium hydroxide (44.88 g, 0.8 mol) in methanol ( 1.2 1) was added ethyl-2-methyl-4- methoxyacetoacetate (87.1 g, 0.5 mol) and 2-methyl-2- thiopseudourea sulphate (139.2 g, 0.5 mol). The mixture was stirred at room temperature for 3 hours, the solvent evaporated off, and water (350 ml) added, followed by glacial acetic acid to pH 4. The resulting solid was filtered off, washed and dried to yield the title compound (78.00 g), m.p. 184-186°C.
(iii) 2-(2-Methylphenylamino)-5-methyl-6- (methoxymethyl)pyrimid-4-one 2-methylthio-5-methyl-6-(methoxymethyl)pyrimid-4-one (78 g, 0.39 mol) and o-toluidine (167.00 g, 1.56 mol) were heated to 200°C under nitrogen with stirring for 16 hours. On trituration with ether the product crystallised out and was filtered off, washed and dried (88 g), m.p. 174-176°C.
(iv) 2-(2-Methylphenylamino)-4-chloro-5-methyl-6- (methoxymethyl)pyrimidine. 2-(2-Methylphenylamino)-5-methyl-6-(methoxymethyl)- pyrimid-4-one (68.0 g, 0.26 mol) and phosphoryl chloride (500 ml, excess) were heated with stirring under reflux for 1 hour. The excess phosphoryl chloride was
evaporated off and the residue poured onto iced water, neutralised with sodium bicarbonate and extracted using chloroform (x3). The combined extracts were dried, filtered and evaporated to yield the title compound as an oil (70.82 g). (v) 2-(2-Methylphenylamino)-4-(N-methylphenylamino)-5- methyl-6-(methoxymethyl)pyrimidine hydrochloride.
2-(2-Methylphenylamino)-4-chloro-5-methyl-6- (methoxymethyl)pyrimidine (9.0 g, 0.032 mol) and N- methylaniline (4.109 g, 0.038 mol) in 1,4-dioxane (350 ml) were stirred and heated under reflux for 16 hours. On cooling the product crystallised out, and was filtered off, washed and recrystallised from acetone-ether to give the title compound (12.32 g), m.p. 167-168°C.
C21H24N4O .HCl
Found: C 65.73, H 6.57, N 14.43
Requires:C 65.53, H 6.55, N 14.56 Example 40
2-(2-Methylphenylamino)-4-(N-methylphenylamino)-5-methyl-6-(hydroxymethyl)pyrimidine
2-(2-Methylphenylamino)-4-(N-methylphenylamino)-5-methy1-6-(methoxymethyl)pyrimidine hydrochloride (5.6 g, 0.0137 mol) in dichloromethane (25 ml) was cooled to -10°C and boron tribromide (17.18 g, 0.685 mol) in
dichloromethane (10 ml) added dropwise, keeping the temperature between -10 & 0°C. After a further 30 minutes at 0°C the solution was poured on to iced water, basified to pH 14 using sodium hydroxide and extracted using dichloromethane (x3). The organic extracts were combined, dried, filtered and evaporated. The residue was
recrystallised from ethanol and the resulting crystals filtered off, washed and dried to yield the title compound (4.58 g), m.p. 129-130°C.
C20H22N4O
Found: C 71.54, H 6.67, N 16.48
Requires :C 71.83, H 6.63, N 17.75
Example 41 2-(2-Phenylamino)-4-(N-methylphenylamino)-5,6,7,8-tetrahydroquinazoline hydrochloride
(i) 2-Methylthio-4-oxo-5,6,7,8-tetrahydroquinazoline Ethyl 2-oxocyclohexanecarboxylate (53 g, 0.312 mol) and S-methyl thiouronium sulphate (82 g, 0.312 mol) were added to a solution of potassium hydroxide (28 g, 0.5 mol) in methanol (500 ml). The mixture was stirred at room temperature for 16h, poured into water (1.5 1), acidified with glacial acetic acid, and stirred for 30 min before filtering off the product, washing with water and drying; yield 36 g (55%), m.p. 233-240°C.
(ii) 2-(Phenylamino)-4-oxo-5,6,7,8-tetrahydroquinazoline
A mixture of 2-methylthio-4-oxo-5,6,7,8- tetrahydroquinazoline (20 g, 0.102 mol) and aniline
(50 ml, excess) was heated at 200°C for 16h, then allowed to cool. The solid mass was triturated with ether, and the solid product filtered off, washed with ether and dried; yield 21 g (85%), m.p. 267-270°C. (iii) 4-Chloro-2-(2-phenylamino)-5,6,7,8- tetrahydroquinazoline
2-Phenylamino-4-oxo-5,6,7,8-tetrahydroquinazoline (10 g, 41.4 mmol) and phosphoryl chloride (100 ml, excess) were heated under reflux for 3 hours, then evaporated to dryness. The oil was added carefully to ice/ammonia, and extracted with chloroform. The extracts were washed with sodium bicarbonate solution and water, dried and
evaporated to give an oil, which was triturated with ether to obtain the title compound; yield 7.1 g (67%),
m.p. 123-125°C.
(iv) 2-(2-Phenylamino)-A-(N-methylphenylamino)-5,6,7,8- tetrahydroquinazoline hydrochloride
4-Chloro-2-(2-ρhenylamino)-5,6,7,8-tetrahydro- quinazoline (2.0 g, 77 mmol) and N-methylaniline (5 ml, excess) were heated to 200°C for 3 hours. Chromatography (silica, chloroform), conversion to the hydrocchloride and crystallisation from ethanol/ether gave the title compound (0.48 g, 19%), m.p. 242-245°C. C21H22N4 .HCl
Found C 68.49, H 6.44, N 15.22, Cl 9.63
Requires C 68.74, H 6.32, N 15.27, Cl 9.66 Example 42
2-(2-Phenylamino)-4-(N-methyl2-methylphenylamino)-5,6,7,8- tetrahydroquinazoline hydrochloride A mixture of 4-chloro-2-(phenylamino)-5,6,7,8- tetrahydroquinazoline (4.0 g, 15.4 mmol) and N-methyl-2- methylaniline (10 ml, excess) was heated to 200°C for 2 hours. Chromatography (silica, chloroform), conversion to the hydrochloride and crystallisation from
ethanol/ether gave the title compound (0.28 g), m.p. 240- 255°C.
C22H24N4 .1.13HCl
Found C 68.36, H 6.57, N 14.32, Cl 10.08
Requires C 68.51, H 6.51, N 14.53, Cl 10.39
Example 43
2-(2-Methylphenylamino)-4-(N-methylphenylamino)-thiopyrano[3,2-d]pyrimidine hydrochloride
(i) 7,8-Dihydro-4-hydroxy-2-(2-methylphenylamino)-6H-thiopyrano[3,2-d]pyrimidine
7,8-Dihydro-4-hydroxy-2-methylthio-6H-thioρyrano[3,2- d]pyrimidine (5 g, 0.023 mol) and 2-methyIphenylamine (10 g) were heated at 200°C for 20h. After allowing to cool, the reaction mixture was diluted with methanol, and the resulting solid was collected by filtration, washed with methanol and dried; yield 4.8 g, m.p. 220-224°C.
(ii) 7,8-Dihydro-4-chloro-2-(2-methylphenylamino)-6H- thiopyrano[3,2-d]pyrimidine
7,8-Dihydro-4-hydroxy-2-methylthio-6H-thiopyrano[3,2- d]pyrimidine (4 g, 0.014 mol) and phosphorus oxychloride
(40 ml) were heated under reflux for lh. The excess phosphorus oxychloride was evaporated under reduced pressure. The residue was treated with ice/water, basified with cone, ammonia solution and extracted with chloroform
(3x150 ml). The chloroform extracts were combined, dried over magnesium sulphate, filtered and evaporated under reduced pressure to give the title compound as an oil; yield 4.2 g.
(iii) 7,8-Dihydro-4-(N-methylphenylamino)-2-(2- methylphenylamino)-6H-thiopyrano[3,2-d]pyrimidine
hydrochloride.
7,8-Dihydro-4-chloro-2-(2-methylphenylamino)-6H- thiopyrano[3,2-d]pyrimidine (3 g, 0.01 mol) and N- methylaniline (2.2 g, 0.02 mol) were heated at 150°C for lh. After allowing to. cool down the reaction mixture was diluted with diethyl ether, and the resulting solid was collected by filtration, washed with ether and dried. The solid was recrystallized from ethanolic HCl, then ethanol, to give the title compound; yield 1.4 g, m.p. 224-226°C.
C21H22N4S .HCl
Found C 62.93, H 5.79, N 13.74, S 7.81, Cl 8.81
Requires C 63.22, H 5.81, N 14.04,. S 8.04, Cl 8.89 Example 44
2-(2-Methylphenylamino)-4-(N-methylphenylamino)-5,7-dihydrothieno[3,4-d]pyrimidine hydrochloride
(i) 2-(2-Methylthio)-4-oxo-5,7-dihydrothieno[3,4- d]pyrimidine
Methyl-3-oxotetrahydrothiophene-4-carboxylate (32.0 g, 0.2 mbl) and S-methylisothiouranium sulphate (55.6 g, 0.2 mol) were added to a solution of potassium hydroxide
(17.9 g, 0.32 mol) in methanol (300 ml). The mixture was stirred at room temperature for 16 hours, then poured into water (approx. 3 1). The mixture was acidified with acetic acid, the white solid filtered off, washed with water and dried; yield 34.2 g (85%), m.p. 270-273°C.
(ii) 2-[(2-Methylphenyl)amino]-4-oxo-5,7-dihydrothieno[3,4- d]pyrimidine
2-(2-Methylthio)-4-oxo-5,7-dihydrothieno[3,4- d]pyrimidine (32 g, 0.16 mol) was mixed with o-toluidine
(100 ml, excess) and the mixture stirred and heated at
200°C for 6 hours, then allowed to cool. The solid mass was was triturated with diethyl ether, and the grey coloured solid filtered off, washed with ether and dried; yield 30 g (73%), m.p. 247-251°C.
(iii) 2-[(2-Methylphenyl)amino]-4-chloro-5,7- dihydrothieno[3,4-d]pyrimidine
2-[(2-Methylphenyl)amino]-4-oxo-5,7-dihydrothieno- [3,4-d]pyrimidine (30 g, 0.115 mol) was mixed with
phosphoryl chloride (150 ml, excess) and the mixture was stirred under reflux for 2 hours, then evaporated to dryness. The residual oil was treated with ice-water, extracted with 3 x 100 ml CHCI3, the extracts washed with sat. NaHCO3 and water, dried over MgSO4, and the solvent evaporated. The dark oil was purified by silica gel chromatography and eluted with CHCl3; yield 6.0 g (18%).
(iv) 2-[(2-Methylphenyl)amino]-4-(N-methyl-2- methylphenyl)amino-5,7-dihydrothieno[3,4-d]pyrimidine
2-[(2-Methylphenyl)amino]-4-chloro-5,7- dihydrothieno[3,4-d]pyrimidine (2.0 g, 7.22 mmol) was mixed with N-methyl aniline (0.91 g, 8.59 mmol) in 1,4- dioxane (80 ml). The mixture was stirred under reflux for 16 hours, then evaporated to dryness. The residual solid was triturated with diethyl ether then recrystallized from aqueous ethanol; yield 1.4 g (58%), m.p. 195-198°C.
C20H20N4S .0.7HCl .0.6H2O
Calc: C 62.43, H 5.73, N 14.56, Cl 6.45
Found: C 62.57, H 5.53, N 14.71, Cl 6.64
Example 45
2-(2-Methylphenylamino)-4-(N-methyl-2-methylphenylamino)- 5,7-dihydrothieno[3,4-d]pyrimidine
2-[2-(2-methylphenyl)amino]-4-chloro-5,7- dihydrothieno[3,4-d]pyrimidine (5.0 g, 0.018 mol) was mixed with N-methyl-o-toluidine (2.79 g, 0.0216 mol) and fused at 160°C for 2 hours. After cooling, the oil was triturated with diethyl ether and the resulting solid filtered off and chromatographed (silica gel, CHCI3);
yield 2.76 g (42%), m.p. 162-165°C. C21H22N4S
Calc: C 69.58, H 6.11, N 15.46, S 8.85
Found: C 69.52, H 6.09, N 15.35, S 9.05 Example 46
2-(2-Methylphenylamino)-4-(N-methyl-2-methylphenylamino)- 6-oxo-5,7-dihydrothieno[3,4-d]pyrimidine A solution of m-chloroperbenzoic acid (0.61 g, 3.58 mmol) in dry dichloromethane (20 ml) was added dropwise to a stirred solution of 2-[(2-methylphenyl)amino]-4-(N- methyl-2-methylphenyl)amino-5,7- dihydrothieno[3,4-d]pyrimidine (1.0 g, 2.76 mmol) in dry dichloromethane (25 ml) at -35° to -40°C. The mixture was stirred for 1 hour at this temperature then allowed to stand overnight. Ammonia gas was bubbled through the solution for 5 min, then the deposited solid was filtered off, washed with dichloromethane and discarded. The combined filtrate was evaporated to dryness and the residual oil was purified by silica gel chromatography, eluted with CHCI3. The product was obtained as an orange coloured solid; yield.0.38 g (38%), m.p. 100-105°C.
C21H22N4OS .0.4H2O .0.1C2H5OH
Calc: C 65.23, H 6.04, N 14.35, S 8.22
Found: C 64.90, H 5.85, N 14.39, S 8.41
Example 47 2-[(2-Methylphenylamino-4-(N-methyl-2-methylphenylamino)- 6,6-dioxo-5,7-dihydrothieno[3,4-d]pyrimidine A solution of m-chloroperbenzoic acid (3.56 g, 0.0207 mol) in dry dichloromethane (20 ml) was added dropwise with stirring to a solution of 2-[(2-methylphenyl)amino]- 4-(N-methyl-2-methylphenyl)amino-5,7- dihydrothieno[3,4-d]pyrimidine (2.5 g, 0.0069 mol) in dry dichloromethane (50 ml) at 25-30°C. The mixture was stirred at room temperature for 16 hours, ammonia gas bubbled through the solution for 10 min, and the deposited solid filtered off and discarded. The filtrate was columned on silica gel, eluted with chloroform. A second column was required to obtain the product as a pale brown solid, m.p. 177-179°C.
C21H22N4O2S
Calc: C 63.94, H 5.62, N 14.20
Found: C 63.68, H 5.58, N 13.91
Example 48
2-(2-Methylphenylamino)-4-(N-methylphenylamino)-6,7-dihydrothieno[3,2-d]pyrimidine
(i) 2-Thio-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidine
2-Carbomethoxy-3-oxotetrahydrothiophene (55 g, 0.316 mol) was added to a solution of sodium (14.5 g, 0.632 mol) in ethanol (500 ml), followed by the addition of thiourea (24 g, 0.316 mol). The mixture was stirred for 24 hours at room temperature, then the solvent evaporated. The residual solid was dissolved in water, acidified
with glacial acetic acid and the deposited solid filtered off, washed with water, and dried; yield 25 g (42%).
(ii) 2-Methylthio-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidine 2-Thio-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidine (25 g, 0.134 mol) was added to a solution of sodium hydroxide (5.88 g, 0.147 mol) in water (50 ml) and ethanol (500 ml). Methyl iodide (20.8 g, 0.147 mol) was added, and the mixture was stirred under reflux for 16 hours. After cooling, the solid was filtered off, washed with diethyl ether and dried; yield 19.5 g (69%), m.p. 265-270°C.
(iii) 2-[(2-Methylphenyl)amino]-4-oxo-6,7- dihydrothieno[3,2-d]pyrimidine
A mixture of 2-methylthio-4-oxo-6,7-dihydrothieno- [3,2-d]pyrimidine (19.5 g, 0.0975 mol) and o-toluidine (80 ml, excess) was stirred and heated at 180-200°C for 16 hours. After cooling, the mixture was poured into diethyl ether (600 ml) and stirred for 30 min at room temperature, then the solid was filtered off, washed with ether and dried; yield 16.1 g (64%), m.p. 249-252°C. (iv) 2-[(2-Methylphenyl)amino]-4-chloro-6,7- dihydrothieno[3,2-d]pyrimidine
2-[(2-Methylphenyl)amino]-4-oxo-6,7-dihydrothieno- [3,2-d]pyrimidine (11.0 g, 0.0424 mol) was mixed with phosphoryl chloride (150 ml, excess) and stirred under reflux for 90 min. The excess acid chloride was removed by evaporation, the residual oil treated with ice/water and extracted with CHCI3, then the extracts were washed with sat. NaHCO3 and water, dried over MgSO4 and the solvent evaporated leaving an oil; yield 12.3 g (greater than theoretical), used without further purification.
(v) 2-[(2-Methylphenyl)amino)-4-(N-methylphenyl)amino]- 6,7-dihydrothieno[3,2-d]pyrimidine 2-[(2-Methylphenyl)amino]-4-chloro-6,7- dihydrothieno [3,2-d]pyrimidine (2.5 g, 9 mmol, crude) was mixed with N-methylaniline (9 ml, excess) and the mixture was stirred at 200°C for 2 hours. After cooling, the product was purified by silica gel chromatography, eluted with EtOAc/pet. ether (1:4). The title compound was obtained as a pale brown solid; yield 1.1 g (34%), m.p. 184-185°C.
C20H20N4S .0-3H2O
Calc: C 67.88, H 5.88, N 15.83, S 9.08
Found: C 67.71, H 5.77, N 15.70, S 9.06
Example 49 2-(2-Methylphenylamino)-4-(N-methyl-2-methylphenylamino)- 6,7-dihydrothieno[3,2-d]pyrimidine
A mixture of 2-[(2-Methylphenyl)amino]-4-chloro-6,7- dihydrothieno[3,2-d]pyrimidine (4.9 g, 0.0176 mol) and N- methyl-o-toluidine (15 ml, excess) was stirred at 200°C for 3 hours. After cooling, the crude oil was dissolved in CHCI3 and the oil purified by silica gel
chromatography, eluted with CHCI3. A further column was required to obtain the product as a grey coloured solid, m.p. 162-165°C.
C21H22N4S
Calc: C 69.58, H 6.12, N 15.46
Found: C 69.63, H 6.07, N 15.31 Example 50
2-(2-Methylphenylamino)-4-(N-methylphenylamino)- thiopyrano[4,3-d]pyrimidine hydrochloride (i) 2-(Methylthio)thiopyrano[4,3-d]pyrimidin-4-one
To a solution of potassium hydroxide (1.08 g, 19 mmol) in methanol (25 ml) was added 3-carbomethoxytetrahydro- 1,4-thiapyrone (2.0 g, 12 mmol) and S-methylisothiouronium sulphate (3.34 g, 12 mmol). After stirring at room temperature for 2 hours, the solution was evaporated to low volume, poured into water (150 ml) and acidified to pH 4 with glacial acetic acid. The white solid which
precipitated was filtered off, washed with water and dried to give the title compound (0.81 g), m.p. 212°C.
(ii) 2-[(2-Methylphenyl)amino]thiopyrano[4,3-d]pyrimidin-4- one
A mixture of 2- (methylthio) thiopyrano [4,3-d]pyrimidin-
4-one (18.0 g, 84 mmol) and o-toluidine (63 g, excess) was heated at 160°C for 17 hours. Excess toluidine was distilled off under reduced pressure, and the residue boiled with ethanol to give a yellow solid. This was filtered off and washed with ether to give the title compound (15.6 g), m.p. 237-240°C.
(iii) 2-[(2-Methylphenyl)amino]-4-chlorothiopyrano- [4,3-d]pyrimidine
A mixture of 2-[(2-methylphenyl)amino]thiopyrano- [4,3-d]pyrimidin-4-one (13.46 g, 49 mmol) and phosphoryl chloride (40 ml, excess) was heated under reflux for 3 hours. The excess phophoryl chloride was evaporated under reduced pressure, and the residue treated with ice-cold water, then extracted 3x with chloroform. The combined extracts were washed with aqueous sodium bicarbonate, water and brine, dried and evaporated to a dark red oil. Chromatography (silica, CH2Cl2/MeOH) gave the title compound as a yellow oil (4.33 g).
(iv) 2-[(2-Methylphenyl)amino]-4-(N-methylphenylamino)- thiopyrano[4,3-d]pyrimidine hydrochloride
A solution of 2-[(2-methylphenyl)amino]-4- chlorothiopyrano[4,3-d]pyrimidine (2.0 g, 6.9 mmol) and N- methylaniline (0.88 g, 8.2 mmol) in dioxan (60 ml) was heated under reflux for 16 hours. The solvent was
evaporated, and the residue crystallised from ethanol to yield the title compound (0.92 g), m.p. 225°C.
C21H22N4S .HCl
Found C 63.26, H 5.82, N 14.18, Cl 8.73
Requires C 63.22, H 5.81, N 14.04, Cl 8.89
Example 51
2-(2-Methylphenylamino)-4-(N-methylphenylamino)6- oxothiopyrano[4,3-d]pyrimidine
A solution of 2-[(2-methylphenyl)amino]-4-(N- methylphenylamino)thiopyrano[4,3-d]pyrimidine
hydrochloride (2.0 g, 5 mmol) in dichloromethane was washed with aqueous sodium bicarbonate then brine, dried over potassium carbonate, and the drying agent filtered off. The filtrate was cooled to -40°C, and a solution of m-chloroperbenzoic acid (1.12 g, 6.5 mmol) in
dichloromethane added dropwise. After a further 0.75 h at -40°C, the cooling bath was removed and ammonia gas passed through the solution for 5 min. The precipitate was filtered off on celite, and the filtrate evaporated to an orange oil, which crystallised on trituration with ether. Recrystallisation from chloroform/ethanol, then from methanol, gave the title compound (0.75 g), m.p. 186°C.
C21H22N4OS .0.9% w/w CH3OH
Found C 66.05, H 5.88, N 14.69, S 8.75
Requires C 66.38, H 6.09, N 14.66, S 8.39
Biological Data.
(A) H+K+ATPase Activity. The effects of a single high concentration (100 μM) of a compound of structure (I) on K-stimulated ATPase activity in lyophilised gastric vesicles was determined. Preferred compounds of structure (I) were also tested over a range of concentrations to determine IC50 values.
(i) Preparation of lyophilised gastric vesicles
(H/K-ATPase).
Lyophilised gastric vesicles were prepared from pig fundic mucosa after the method of Keeling et. al.
(Biochem. Pharmacol., 34, 2967, 1985).
(ii) K+-stimulated ATPase activity. K+-stimulated ATPase activity was determined at 37° in the presence of the following : 10 mM Pipes/Tris buffer pH 7.0, 2 mM MgSO4, 1 mM KCl, 2 mM Na2ATP and 3-6 μg protein/ml lyophilised gastric vesicles. After incubation for 30 minutes, the inorganic phosphate hydrolysed from ATP was determined by the method of Yoda and Hokin
(Biochem. Biophys. Res. Commun. 40, 880, 1970).
Compounds of structure (I) were dissolved in
dimethylsulphoxide which up to the highest concentration used had no effect on K+-stimulated ATPase activity. The effect of the highest concentration of each compound of structure (I) on the recovery of a standard amount of inorganic phosphate was also determined. (iϋ) Results.
The compounds of the examples had IC50 values of less than 50μM.
Example A
A tablet for oral administration is prepared by combining
Mg/Tablet
Compound of structure (I) 100
lactose 153
Starch 33
crospovidone 12
microcrystalline cellulose 30
magnesium stearate 2
330 mg into a 9 mm tablet.
Example B An injection for parenteral administration is prepared from the following
%w:w
Compound of structure (I) 0,50% (w:v)
1M citric acid 30% (v:v)
sodium hydroxide (qs) to pH 3.2
water for injection EP to 100 ml
The compound of structure (I) is dissolved in the citric acid and the pH slowly adjusted to pH 3.2 with the sodium hydroxide solution. The solution was then made up to 100 ml with water, sterilised by filtration and sealed into appropriately sized ampoules and vials.

Claims

Claims .
1. A compound of structure (I)
Figure imgf000072_0001
in which
Ar is a phenyl ring which can be optionally substituted by one to three groups selected from hydroxy, halogen, CF3, C1-4alkyl, C1-4alkoxy, C1-4alkylthio, cyano, amino, carbamoyl carboxy or C1-4alkanoyl;
R1 is hydrogen or C1-4alkyl; R2 and R3 are the same or different and are each hydrogen, C1-4alkyl or Ar1 where Ar1 is as defined for Ar; or R2 and R3 together with the nitrogen atom to which they are attached form a saturated or unsaturated ring optionally containing one or more further heteroatoms. one of R4 and R5 is hydrogen or C1-4alkyl; and the other is hydrogen, C1-4alkyl, hydroxyC1-4alkyl,
C1-4alkoxyC1-4alkyl, amino, C1-4alkanoyl,
C1-4alkylthioC1-4alkyl, Ar2 (CH2)nOC1-4alkyl,
in which Ar2 is an optionally substituted phenyl ring as defined for Ar and n is 0 to 4; or -(CH2)mAr3, in which m is 1 to 4 and Ar3 is an optionally
substituted phenyl ring as defined for Ar; or R4 and R5 together with the carbon atoms to which they are attached form a 5- or 6-membered ring, optionally containing one or more heteroatoms; or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 in which one of R2 and R3 is hydrogen and the other is an optionally substituted phenyl ring.
3. A compound according to claim 1 which is
5,6-dimethyl-2-[(2-methylphenyl)amino]-4-(N-methyl-2- methylphenyl amino)pyrimidine hydrochloride,
5,6-dimethyl-2-[(2-methylphenyl)amino]-4-(N-methyl- phenylamino)pyrimidine hydrochloride,
5-methyl-6-n-propyl-2-[(2-methylphenyl)amino]-4-(N- methylphenylamino) pyrimidine hydrochloride,
2-[(2-methylphenyl)amino]-4-(N-methy1-2-methylphenylamino)- 5,6,7,8-tetrahydroquinazoline hydrochloride, or
2-(2-phenylamino)-4-(N-methylphenylamino)-5,6,7,8-tetra- hydroquinazoline hydrochloride.
4. A process for preparing a compound according to claim 1 which comprises reaction of a compound of structure (II)
Figure imgf000073_0001
in which R3, R4 and R5 are as described for
structure (I), and X is a group displaceable by an amine, with an amine of structure ArNR1H in which Ar and R1 are as described for structure (I), and optionally
thereafter, forming a pharmaceutically acceptable salt.
5. A pharmaceutical composition comprising a compound of structure (I) or a pharmaceutically acceptable salt thereof as described in claim 1 in association with a pharmaceutically acceptable carrier.
6. A compound of structure (I) for use in therapy.
7. A compound of structure (II) as described in claim 4.
PCT/EP1991/001007 1990-06-06 1991-06-01 Diaminopyrimidine compounds WO1991018887A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909012592A GB9012592D0 (en) 1990-06-06 1990-06-06 Compounds
GB9012592.3 1990-06-06

Publications (1)

Publication Number Publication Date
WO1991018887A1 true WO1991018887A1 (en) 1991-12-12

Family

ID=10677143

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1991/001007 WO1991018887A1 (en) 1990-06-06 1991-06-01 Diaminopyrimidine compounds

Country Status (3)

Country Link
AU (1) AU7971691A (en)
GB (1) GB9012592D0 (en)
WO (1) WO1991018887A1 (en)

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
WO1996010565A1 (en) * 1994-10-04 1996-04-11 Istituto Superiore Di Sanita' Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them
WO1997042186A1 (en) * 1996-05-04 1997-11-13 Yuhan Corporation Process for preparation of pyrimidine derivatives
EP0865434A4 (en) * 1995-01-06 1998-09-23
EP0945443A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
EP0945442A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
WO2000003998A1 (en) * 1998-07-17 2000-01-27 Novirio Pharmaceuticals Limited Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them
WO2000039101A1 (en) * 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds
US6107301A (en) * 1993-10-12 2000-08-22 Dupont Pharmaceuticals Company 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
US6197779B1 (en) 1998-03-27 2001-03-06 Janssen Pharmaceutica, Inc. HIV inhibiting pyrimidine derivative
WO2001023362A2 (en) * 1999-09-24 2001-04-05 Abbott Gmbh & Co. Kg Rate-controlled particles
US6252076B1 (en) 1996-05-04 2001-06-26 Yuhan Corporation Process for preparation of pyrimidine derivatives
EP1142881A1 (en) * 1999-01-14 2001-10-10 Meiji Seika Kaisha Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
WO2001085700A3 (en) * 2000-05-08 2002-02-07 Janssen Pharmaceutica Nv Hiv replication inhibiting pyrimidines and triazines
WO2001085699A3 (en) * 2000-05-08 2002-02-28 Janssen Pharmaceutica Nv Prodrugs of hiv replication inhibiting pyrimidines
US6352993B1 (en) 1997-03-27 2002-03-05 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
US6545007B2 (en) 2000-11-17 2003-04-08 Idenix (Cayman) Limited Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines
US6545008B1 (en) 1998-11-17 2003-04-08 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
WO2003037877A1 (en) * 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS
US6632820B1 (en) 1998-08-29 2003-10-14 Astrazeneca Ab Pyrimidine compounds
US6649608B2 (en) 2000-03-01 2003-11-18 Astrazeneca Ab 2,4-di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents
US6670368B1 (en) 1999-04-06 2003-12-30 Astrazeneca Ab Pyrimidine compounds with pharmaceutical activity
US6710052B2 (en) 2000-03-01 2004-03-23 Astrazeneca Pyrimidine compounds
US6716831B1 (en) 1999-03-06 2004-04-06 Astrazeneca Ab 2,4-diamino-pyrimidine deprivatives having anti-cell proliferative activity
EP1471915A2 (en) * 2002-02-01 2004-11-03 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US6838464B2 (en) 2000-03-01 2005-01-04 Astrazeneca Ab 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents
US6844341B2 (en) 2001-02-17 2005-01-18 Astrazeneca Ab Pyrimidine derivatives for inhibition of cell proliferation
US6855719B1 (en) 1999-08-21 2005-02-15 Astrazeneca Ab Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives
US6906065B2 (en) 2000-03-28 2005-06-14 Astrazeneca Ab 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
US6908920B2 (en) 2000-07-11 2005-06-21 Astrazeneca Ab Pyrimidine derivatives
US6939872B2 (en) 2001-05-30 2005-09-06 Astrazeneca Ab 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
US6969714B2 (en) 2000-09-05 2005-11-29 Astrazeneca Ab Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
WO2006035068A3 (en) * 2004-09-30 2006-08-31 Tibotec Pharm Ltd Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7153964B2 (en) 2000-03-01 2006-12-26 Astrazeneca Ab Pyrimidine compounds
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
US7166599B2 (en) 2001-10-17 2007-01-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Trisubstituted pyrimidines
US7173028B2 (en) 2001-10-17 2007-02-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives
US7176212B2 (en) 1998-08-29 2007-02-13 Astrazeneca Ab 2,4-diamino pyrimidine compounds having anti-cell proliferative activity
US7175854B2 (en) 2000-12-07 2007-02-13 Altana Pharma Ag Pharmaceutical preparation comprising an active dispersed on a matrix
US7241458B1 (en) 1999-09-24 2007-07-10 Janssen Pharmaceutica N.V. Antiviral compositions
WO2008061112A2 (en) * 2006-11-14 2008-05-22 Myriad Genetics, Inc. Pharmaceutical compounds as inhibitors of cell proliferation and the use thereof
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
US7427626B2 (en) 2003-05-16 2008-09-23 Astrazeneca Ab 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
US7446105B2 (en) 2002-03-09 2008-11-04 Astrazeneca Ab Pyrimidine compounds
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7465728B2 (en) 2002-03-09 2008-12-16 Astrazeneca Ab Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity
US7485638B2 (en) 2002-03-09 2009-02-03 Astrazeneca Ab Pyrimidine compounds
US7514445B2 (en) 2001-11-01 2009-04-07 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors)
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
US7579344B2 (en) 2003-05-16 2009-08-25 Astrazeneca Ab Pyrimidine derivatives possessing cell-cycle inhibitors activity
US7655652B2 (en) 2004-02-03 2010-02-02 Astrazeneca Ab Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
US7705009B2 (en) 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
US7745428B2 (en) 2005-09-30 2010-06-29 Astrazeneca Ab Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
US20110092499A1 (en) * 2007-11-15 2011-04-21 Ym Biosciences Australia Pty Ltd N-containing heterocyclic compounds
US7951397B2 (en) 2002-02-20 2011-05-31 Nycomed Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US9580392B2 (en) 2001-08-13 2017-02-28 Janssen Pharmaceutica Nv HIV replication inhibiting pyrimidines
US10172856B2 (en) 2017-04-06 2019-01-08 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives as histamine H4 modulators
US10391094B2 (en) 2010-11-07 2019-08-27 Impact Biomedicines, Inc. Compositions and methods for treating myelofibrosis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB584917A (en) * 1942-11-02 1947-01-27 Parke Davis & Co Secondary aromatic amines and process for obtaining the same
US2748124A (en) * 1954-05-06 1956-05-29 Searle & Co 1-(4-anilino-2-pyrimidino)-3-alkylureas
US3478030A (en) * 1966-06-27 1969-11-11 Abbott Lab Benzamide substituted anilino aminopyrimidines
GB1229413A (en) * 1967-06-14 1971-04-21
EP0322133A1 (en) * 1987-12-03 1989-06-28 SmithKline Beecham Intercredit B.V. Quinazoline derivatives
WO1990012790A1 (en) * 1989-04-21 1990-11-01 Imperial Chemical Industries Plc Pyrimidine derivatives
EP0404356A1 (en) * 1989-05-30 1990-12-27 Smithkline Beecham Intercredit B.V. Substituted thienopyrimidine derivatives, their preparation, pharmaceutical compositions and medical use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB584917A (en) * 1942-11-02 1947-01-27 Parke Davis & Co Secondary aromatic amines and process for obtaining the same
US2748124A (en) * 1954-05-06 1956-05-29 Searle & Co 1-(4-anilino-2-pyrimidino)-3-alkylureas
US3478030A (en) * 1966-06-27 1969-11-11 Abbott Lab Benzamide substituted anilino aminopyrimidines
GB1229413A (en) * 1967-06-14 1971-04-21
EP0322133A1 (en) * 1987-12-03 1989-06-28 SmithKline Beecham Intercredit B.V. Quinazoline derivatives
WO1990012790A1 (en) * 1989-04-21 1990-11-01 Imperial Chemical Industries Plc Pyrimidine derivatives
EP0404356A1 (en) * 1989-05-30 1990-12-27 Smithkline Beecham Intercredit B.V. Substituted thienopyrimidine derivatives, their preparation, pharmaceutical compositions and medical use

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 108, 1988, page 670, abstract no. 204585c, (Columbus, Ohio, US), K.M. GHONEIM et al.: "Synthesis and evaluation of some 2-, 4-, and 2,4-disubstituted-6-methylpyrimidine derivatives for antimicrobial activity", & EGYPT. J. PHARM. SCI. 1987, 28(1-4), 117-26, see the abstract *
CHEMICAL ABSTRACTS, vol. 108, 1988, page 724, abstract no. 56043g, (Columbus, Ohio, US), K.M. GHONEIM et al.: "Synthesis and evaluation of some 2-, 4- and 2,4-di-substituted-6-methylpyrimidine derivatives for antimicrobial activity", & J. INDIAN CHEM. SOC. 1986, 63(10), 914-17, see the abstract *
CHEMICAL ABSTRACTS, vol. 114, 1991, page 684, abstract no. 62037y, (Columbus, Ohio, US), K.M. GHONEIM et al.: "Synthesis of some Mannich bases of 2- and 4-amino- and 2,4-diamino-6-methylpyrimidines as potential biodynamic agents", & EGYPT. J. CHEM. 1987, (PUB. 1989), 30(6), 295-304, see the abstract *
CHEMICAL ABSTRACTS, vol. 66, 1967, page 2735, abstract no. 28731a, (Columbus, Ohio, US), C.A.R. HURT et al.: "The synthesis of pyrimidoquinazolones", & TETRAHEDRON SUPPL. NO. 7, 227-32(1966), see the abstract *
CHEMICAL ABSTRACTS, vol. 71, 1969, page 295, abstract no. 30453h, (Columbus, Ohio, US), E.A. ARUTYUNYAN et al.: "Direct amination of uracils and related compounds", & IZV. AKAD. NAUK SSSR, SER. KHIM. 1969, (3), 655-62, see the abstract *
CHEMICAL ABSTRACTS, vol. 71, 1969, pages 295 *
CHEMICAL ABSTRACTS, vol. 93, 1980, pages 925-926 *
CHEMICAL ABSTRACTS, vol. 93, 1980, pages 925-926, abstract no. 46582q, (Columbus, Ohio, US), A.V. IVASHCHENKO et al.: "Synthesis and study of derivatives of 2,4-diamino- and 2-amino-4-(1H-pyrazol-1-yl)pyrimidine", & KHIM. GETEROTSIKL. SOEDIN. 1980, (3), 404-7, see the abstract *
CHEMICAL ABSTRACTS, vol. 95, 1981, page 648, abstract no. 97712f, (Columbus, Ohio, US), D. GHOSH: "2,4-Bis(arylamino)-6-methylpyrimidines as antimicrobial agents", & J. INDIAN CHEM. SOC. 1981, 58(5), 512-13, see the abstract *
JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 21, July-August 1984, (US), H. GERSHON et al.: "Pyrimidines. 7. A Study of the chlorination of pyrimidines with phosphorus oxychloride in the presence of N,N-dimethylaniline", pages 1161-1167, see pages 1162-1166 *
JOURNAL OF HETROCYCLIC CHEMISTRY, vol. 21, July-August 1984, (US), H. Gershon et al.:"Pyrimidines. 7. A study of the chlorination of pyrimidines with phosphorus oxychloride in the presence of N,N-dimethylaniline", pages 1161-1167 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 11, 1968, (Washington, US), G.J. ATWELL et al.: "Potential antitumor agents. VIII. Bisquaternary salts", pages 690-694, see pages 691-692 *
JOURNAL OF MEDICinal chemistry, vol. 11, 1968, (Washinton, US), G.J. Atwell et al.: "Potential anttumor agents. VIII. Bisquaternay salts", pages 690-694 *

Cited By (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107301A (en) * 1993-10-12 2000-08-22 Dupont Pharmaceuticals Company 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US6342503B1 (en) 1993-10-12 2002-01-29 Dupont Pharmaceuticals Company 1N-alkyl-n-arylpyrimidinamines and derivatives thereof
WO1996010565A1 (en) * 1994-10-04 1996-04-11 Istituto Superiore Di Sanita' Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them
EP0865434A4 (en) * 1995-01-06 1998-09-23
EP0865434A1 (en) * 1995-01-06 1998-09-23 The Picower Institute For Medical Research Compounds and methods of use to treat infectious diseases
WO1997042186A1 (en) * 1996-05-04 1997-11-13 Yuhan Corporation Process for preparation of pyrimidine derivatives
US5990311A (en) * 1996-05-04 1999-11-23 Uhan Corporation Process for preparation of pyrimidine derivatives
US6252076B1 (en) 1996-05-04 2001-06-26 Yuhan Corporation Process for preparation of pyrimidine derivatives
US6352993B1 (en) 1997-03-27 2002-03-05 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
EP1245567A1 (en) 1998-03-27 2002-10-02 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
HRP20000620B1 (en) * 1998-03-27 2009-07-31 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidine derivatives
US6197779B1 (en) 1998-03-27 2001-03-06 Janssen Pharmaceutica, Inc. HIV inhibiting pyrimidine derivative
US6903213B2 (en) 1998-03-27 2005-06-07 Koenraad Jozef Lodewijk Marcel Andries HIV inhibiting pyrimidine derivatives
US8026248B2 (en) 1998-03-27 2011-09-27 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
BG64702B1 (en) * 1998-03-27 2005-12-30 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidine derivatives
EP0945443A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
WO1999050250A1 (en) * 1998-03-27 1999-10-07 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidine derivatives
CZ299380B6 (en) * 1998-03-27 2008-07-09 Janssen Pharmaceutica N. V. Pyrimidine compound, use of such compound for the preparation of a medicament, pharmaceutical composition containing such compound, process for preparing the pharmaceutical composition and such compound as well as combination and product containing s
KR100643419B1 (en) * 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. ??? inhibiting pyrimidine derivatives
EP0945442A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
US6440986B2 (en) 1998-03-27 2002-08-27 Janssen Pharmaceutica, N.V. HIV Inhibiting pyrimidine derivatives
AP1468A (en) * 1998-03-27 2005-09-23 Janssen Pharmaceutica Nv Hiv inhibiting pyrimidine derivatives.
AU771209B2 (en) * 1998-07-17 2004-03-18 Idenix (Cayman) Limited Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them
WO2000003998A1 (en) * 1998-07-17 2000-01-27 Novirio Pharmaceuticals Limited Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them
US6635636B1 (en) 1998-07-17 2003-10-21 Idenix Pharmaceuticals, Inc. Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them
US6632820B1 (en) 1998-08-29 2003-10-14 Astrazeneca Ab Pyrimidine compounds
US7176212B2 (en) 1998-08-29 2007-02-13 Astrazeneca Ab 2,4-diamino pyrimidine compounds having anti-cell proliferative activity
US6545008B1 (en) 1998-11-17 2003-04-08 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
KR100663773B1 (en) * 1998-12-24 2007-01-03 아스트라제네카 아베 Pyrimidine compounds
WO2000039101A1 (en) * 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds
US6593326B1 (en) 1998-12-24 2003-07-15 Astrazeneca Ab 2,4-diamino pyrimidine compounds having anti-cell proliferative activity
EP1142881A1 (en) * 1999-01-14 2001-10-10 Meiji Seika Kaisha Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
EP1142881A4 (en) * 1999-01-14 2003-05-07 Meiji Seika Kaisha Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
US6716831B1 (en) 1999-03-06 2004-04-06 Astrazeneca Ab 2,4-diamino-pyrimidine deprivatives having anti-cell proliferative activity
US6670368B1 (en) 1999-04-06 2003-12-30 Astrazeneca Ab Pyrimidine compounds with pharmaceutical activity
US6855719B1 (en) 1999-08-21 2005-02-15 Astrazeneca Ab Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives
JP2003518012A (en) * 1999-09-24 2003-06-03 アボット ゲーエムベーハー ウント カンパニー カーゲー Controlled release rate particles
JP4996801B2 (en) * 1999-09-24 2012-08-08 ティボテック ファーマスーティカルズ エルティディ Release rate controlled particles
US7887845B2 (en) 1999-09-24 2011-02-15 Janssen Pharmaceutica Nv Antiviral compositions
US9028876B2 (en) 1999-09-24 2015-05-12 Janssen R&D Ireland Rate-controlled particles
WO2001023362A3 (en) * 1999-09-24 2001-12-06 Knoll Ag Rate-controlled particles
US7241458B1 (en) 1999-09-24 2007-07-10 Janssen Pharmaceutica N.V. Antiviral compositions
WO2001023362A2 (en) * 1999-09-24 2001-04-05 Abbott Gmbh & Co. Kg Rate-controlled particles
US7067522B2 (en) 2000-03-01 2006-06-27 Astrazeneca Ab 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
US6710052B2 (en) 2000-03-01 2004-03-23 Astrazeneca Pyrimidine compounds
US7153964B2 (en) 2000-03-01 2006-12-26 Astrazeneca Ab Pyrimidine compounds
US6649608B2 (en) 2000-03-01 2003-11-18 Astrazeneca Ab 2,4-di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents
US6838464B2 (en) 2000-03-01 2005-01-04 Astrazeneca Ab 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents
US6906065B2 (en) 2000-03-28 2005-06-14 Astrazeneca Ab 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
US7276510B2 (en) 2000-05-08 2007-10-02 Janssen Pharmaceutica, Inc. HIV replication inhibitors
US7034019B2 (en) 2000-05-08 2006-04-25 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
JP2003532713A (en) * 2000-05-08 2003-11-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Prodrugs of pyrimidines that inhibit HIV replication
WO2001085699A3 (en) * 2000-05-08 2002-02-28 Janssen Pharmaceutica Nv Prodrugs of hiv replication inhibiting pyrimidines
WO2001085700A3 (en) * 2000-05-08 2002-02-07 Janssen Pharmaceutica Nv Hiv replication inhibiting pyrimidines and triazines
US6908920B2 (en) 2000-07-11 2005-06-21 Astrazeneca Ab Pyrimidine derivatives
US6969714B2 (en) 2000-09-05 2005-11-29 Astrazeneca Ab Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
US6545007B2 (en) 2000-11-17 2003-04-08 Idenix (Cayman) Limited Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines
US7175854B2 (en) 2000-12-07 2007-02-13 Altana Pharma Ag Pharmaceutical preparation comprising an active dispersed on a matrix
US7951398B2 (en) 2000-12-07 2011-05-31 Nycomed Gmbh Pharmaceutical preparation comprising an active dispersed on a matrix
US6844341B2 (en) 2001-02-17 2005-01-18 Astrazeneca Ab Pyrimidine derivatives for inhibition of cell proliferation
US6939872B2 (en) 2001-05-30 2005-09-06 Astrazeneca Ab 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
US6995159B2 (en) 2001-06-21 2006-02-07 Pfizer Inc. 5-HT receptor ligands and uses thereof
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US9580392B2 (en) 2001-08-13 2017-02-28 Janssen Pharmaceutica Nv HIV replication inhibiting pyrimidines
US10611732B2 (en) 2001-08-13 2020-04-07 Janssen Pharmaceutica Nv HIV replication inhibiting pyrimidines
US10370340B2 (en) 2001-08-13 2019-08-06 Janssen Pharmaceutica Nv HIV replication inhibiting pyrimidines
US9981919B2 (en) 2001-08-13 2018-05-29 Janssen Pharmaceutical N.V. HIV replication inhibiting pyrimidines
US8420630B2 (en) 2001-10-17 2013-04-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives
US7173028B2 (en) 2001-10-17 2007-02-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives
US7709480B2 (en) 2001-10-17 2010-05-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives
US7166599B2 (en) 2001-10-17 2007-01-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Trisubstituted pyrimidines
AU2002363177B2 (en) * 2001-11-01 2008-09-18 Janssen Pharmaceutica N.V. Aminobenzamide derivatives as glycogen synthase kinase 3Beta inhibitors
WO2003037877A1 (en) * 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS
US7514445B2 (en) 2001-11-01 2009-04-07 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors)
US9018204B1 (en) 2002-02-01 2015-04-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
EP1471915A2 (en) * 2002-02-01 2004-11-03 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7550460B2 (en) 2002-02-01 2009-06-23 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
JP2005516046A (en) * 2002-02-01 2005-06-02 ライジェル ファーマシューティカルズ, インコーポレイテッド 2,4-pyrimidinediamine compounds and their uses
US9913842B2 (en) 2002-02-01 2018-03-13 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
EP1471915A4 (en) * 2002-02-01 2006-02-15 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7498435B2 (en) 2002-02-01 2009-03-03 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US10709703B2 (en) 2002-02-01 2020-07-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9346765B2 (en) 2002-02-01 2016-05-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7820819B2 (en) 2002-02-01 2010-10-26 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US10682350B2 (en) 2002-02-01 2020-06-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9416112B2 (en) 2002-02-01 2016-08-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
HRP20040684B1 (en) * 2002-02-01 2014-07-04 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8334296B2 (en) 2002-02-01 2012-12-18 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7329672B2 (en) 2002-02-01 2008-02-12 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7329671B2 (en) 2002-02-01 2008-02-12 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7589200B2 (en) 2002-02-01 2009-09-15 Rigel Pharmaceuticals, Inc. 5-Fluoro-4N-phenyl-4-pyrimidineamine compounds
JP4658477B2 (en) * 2002-02-01 2011-03-23 ライジェル ファーマシューティカルズ, インコーポレイテッド 2,4-pyrimidinediamine compounds and their uses
US7655797B2 (en) 2002-02-01 2010-02-02 Rigel Pharmaceuticals, Inc. Intermediates for making 2,4-pyrimidinediamine compounds
US7332484B2 (en) 2002-02-01 2008-02-19 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7803939B2 (en) 2002-02-01 2010-09-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7951397B2 (en) 2002-02-20 2011-05-31 Nycomed Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US8431154B2 (en) 2002-02-20 2013-04-30 Takeda Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
US9468598B2 (en) 2002-02-20 2016-10-18 Astrazeneca Ab Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
US7485638B2 (en) 2002-03-09 2009-02-03 Astrazeneca Ab Pyrimidine compounds
US7465728B2 (en) 2002-03-09 2008-12-16 Astrazeneca Ab Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity
US7446105B2 (en) 2002-03-09 2008-11-04 Astrazeneca Ab Pyrimidine compounds
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8557806B2 (en) 2002-07-29 2013-10-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7812029B1 (en) 2002-07-29 2010-10-12 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7825116B2 (en) 2002-07-29 2010-11-02 Rigel Pharmaceuticals, Inc. N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines
US7615634B2 (en) 2003-02-10 2009-11-10 Hoffmann-La Roche Inc. 4-aminopyrimidine-5-one derivatives
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
US7427626B2 (en) 2003-05-16 2008-09-23 Astrazeneca Ab 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors
US7579344B2 (en) 2003-05-16 2009-08-25 Astrazeneca Ab Pyrimidine derivatives possessing cell-cycle inhibitors activity
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US9751893B2 (en) 2003-07-30 2017-09-05 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
US7560466B2 (en) 2003-07-30 2009-07-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7655652B2 (en) 2004-02-03 2010-02-02 Astrazeneca Ab Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
JP2008514680A (en) * 2004-09-30 2008-05-08 テイボテク・フアーマシユーチカルズ・リミテツド HIV inhibitory 5-carbocyclic or heterocyclic substituted pyrimidines
US7531548B2 (en) 2004-09-30 2009-05-12 Tibotec Pharmaceuticals Ltd HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines
WO2006035068A3 (en) * 2004-09-30 2006-08-31 Tibotec Pharm Ltd Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
US7851480B2 (en) 2004-11-24 2010-12-14 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
US7989448B2 (en) 2005-01-19 2011-08-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7563892B1 (en) 2005-01-19 2009-07-21 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4 pyrimidinediamine compounds and their uses
US7538108B2 (en) 2005-01-19 2009-05-26 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US10577381B2 (en) 2005-01-19 2020-03-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9266912B2 (en) 2005-01-19 2016-02-23 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8476263B2 (en) 2005-01-19 2013-07-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8785437B2 (en) 2005-01-19 2014-07-22 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8211888B2 (en) 2005-01-19 2012-07-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9532998B2 (en) 2005-01-19 2017-01-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8211889B2 (en) 2005-01-19 2012-07-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7745428B2 (en) 2005-09-30 2010-06-29 Astrazeneca Ab Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
US7705009B2 (en) 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
WO2008061112A3 (en) * 2006-11-14 2008-10-30 Myriad Genetics Inc Pharmaceutical compounds as inhibitors of cell proliferation and the use thereof
WO2008061112A2 (en) * 2006-11-14 2008-05-22 Myriad Genetics, Inc. Pharmaceutical compounds as inhibitors of cell proliferation and the use thereof
US8354408B2 (en) * 2007-11-15 2013-01-15 Ym Biosciences Australia Pty Ltd N-containing heterocyclic compounds
US9499560B2 (en) 2007-11-15 2016-11-22 Ym Biosciences Australia Pty Ltd N-containing heterocyclic compounds
US20110092499A1 (en) * 2007-11-15 2011-04-21 Ym Biosciences Australia Pty Ltd N-containing heterocyclic compounds
US8765755B2 (en) 2007-11-15 2014-07-01 Ym Biosciences Australia Pty Ltd. N-containing heterocyclic compounds
US10391094B2 (en) 2010-11-07 2019-08-27 Impact Biomedicines, Inc. Compositions and methods for treating myelofibrosis
US10172856B2 (en) 2017-04-06 2019-01-08 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives as histamine H4 modulators

Also Published As

Publication number Publication date
AU7971691A (en) 1991-12-31
GB9012592D0 (en) 1990-07-25

Similar Documents

Publication Publication Date Title
WO1991018887A1 (en) Diaminopyrimidine compounds
JP2896532B2 (en) Novel pyrimidine derivative and method for producing the same
US5064833A (en) Substituted quinazoline derivatives for use in gastrointestinal diseases
EP0322133B1 (en) Quinazoline derivatives
CA3042960C (en) Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof
ES2274526T3 (en) PIRIDO (2,3-D) PYRIMIDINS TO INHIBIT THE CELLULAR PROLIFERATION THROUGH THYROSINAQUINASE.
AU747920B2 (en) Bicyclic pyridine and pyrimidine derivatives as neuropeptide Y receptor antagonists
AU2004279427B2 (en) Compounds and compositions as protein kinase inhibitors
KR100392872B1 (en) Tricyclic Compounds That Can Inhibit Tyrosine Kinase from the Epidermal Growth Factor Receptor Group
AU686339B2 (en) Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
DE60037020T2 (en) ANILINOCHINAZOLINE AS PROTEIN TYROSINE KINASE INHIBITOR
US5280026A (en) Thienopyrimidines
EP0188094A2 (en) Quinazoline derivatives and antihypertensive preparations containing same as effective components
WO1996040142A1 (en) Heterocyclic ring-fused pyrimidine derivatives
NO894228L (en) TIENOPYRIDINES, PREPARATIONS, INTERMEDIATES AND PHARMACEUTICAL PREPARATIONS.
MXPA05001389A (en) Condensed pyridines and pyrimidines with tie2 (tek) activity.
WO2002002568A1 (en) Pyrimidine derivatives and their use for preventing and treating cerebral ischaemia
JP2022523477A (en) A pharmaceutical composition for preventing or treating a pyrrolopyrimidine derivative and a protein kinase-related disease containing the derivative as an active ingredient.
WO1993015056A1 (en) Pyridone derivatives, their preparation and use as medicines
EP0404322B1 (en) Quinazoline derivatives
JP2003500397A (en) 2-NH-pyridones and pyrimidones as MRS inhibitors
EP0126970A2 (en) Anxiolytic and anti-depressant thienopyridine derivatives
EP0404356B1 (en) Substituted thienopyrimidine derivatives, their preparation, pharmaceutical compositions and medical use
SU906379A3 (en) Method for preparing pyrido-(1,2-alpha) pyrimidines derivatives, their salts, or their optically active isomers
JPS6140285A (en) Ring condensed pyrazolo(3,4_d)_pyridin_3_one derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA